Taofeek Owonikoko MD/PhD
Academic Appointment
- Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Education
Degrees
- MS from Emory University
- PhD from Heinrich Heine University
- MBChB from Obafemi Awolowo University
Research
Focus
- My principal research interest is in early drug development with a focus on neuroendocrine cancers, specifically, small cell lung cancer and thyroid cancers. Small cell lung cancer is a disease with very dismal outcome due to a high relapse rate and the lack of an effective treatment option for relapsed disease.
Publications
-
Correction: EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Oncogene Volume: 44 Page(s): 928 - 930
04/01/2025 Authors: Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J -
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
Nat Commun Volume: 16 Page(s): 2324
03/08/2025 Authors: Shu C; Li J; Rui J; Fan D; Niu Q; Bai R; Cicka D; Doyle S; Wahafu A; Zheng X -
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice.
JCO Oncol Pract Volume: 21 Page(s): 292 - 299
03/01/2025 Authors: Dizman N; Bakouny Z; Haykal T; Riano I; Desai A; Butt A; Basu A; Zhao D; Saad E; Saliby RM -
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.
Cancer Volume: 131 Page(s): e35738
02/01/2025 Authors: Sands JM; Champiat S; Hummel H-D; Paulson KG; Borghaei H; Alvarez JB; Carbone DP; Carlisle JW; Choudhury NJ; Clarke JM -
Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer.
Cancers (Basel) Volume: 17
01/28/2025 Authors: Zhang G; Pannucci A; Ivanov AA; Switchenko J; Sun S-Y; Sica GL; Liu Z; Huang Y; Schmitz JC; Owonikoko TK -
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.
Cancer Volume: 131 Page(s): e35680
01/01/2025 Authors: Mahalingam D; Owonikoko TK; Delpassand E; Mulcahy MF; Kalyan A; Ulahannan S; Cheung K; Izumi Y; Johansen M; Madden T -
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Future Oncol Volume: 20 Page(s): 3355 - 3364
12/01/2024 Authors: Ahn M-J; Cho BC; Felip E; Korantzis I; Ohashi K; Majem M; Juan-Vidal O; Handzhiev S; Izumi H; Lee J-S -
SCLC Classification by Platinum Sensitivity in the Era of Immunotherapy: Mere Relic or a Valuable Treasure to Keep?
J Thorac Oncol Volume: 19 Page(s): 193 - 195
02/01/2024 Authors: Owonikoko TK -
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.
Eur Thyroid J Volume: 13
02/01/2024 Authors: Gianoukakis AG; Choe JH; Bowles DW; Brose MS; Wirth LJ; Owonikoko T; Babajanyan S; Worden FP -
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.
Oncologist Volume: 28 Page(s): 1055 - 1063
12/11/2023 Authors: Lalonde CS; Switchenko JM; Behera M; Bilen MA; Owonikoko TK; Kaufman JL; Nooka AK; Lewis CM; Hitron E; Collins H -
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med Volume: 389 Page(s): 2063 - 2075
11/30/2023 Authors: Ahn M-J; Cho BC; Felip E; Korantzis I; Ohashi K; Majem M; Juan-Vidal O; Handzhiev S; Izumi H; Lee J-S -
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
J Clin Oncol Volume: 41 Page(s): 2893 - 2903
06/01/2023 Authors: Paz-Ares L; Champiat S; Lai WV; Izumi H; Govindan R; Boyer M; Hummel H-D; Borghaei H; Johnson ML; Steeghs N -
Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies.
JCO Oncol Pract Volume: 19 Page(s): 278 - 283
05/01/2023 Authors: Chattaraj A; Syed MP; Low CA; Owonikoko TK -
Serum glycomic profile as a predictive biomarker of recurrence in patients with differentiated thyroid cancer.
Cancer Med Volume: 12 Page(s): 6768 - 6777
03/01/2023 Authors: Kudelka MR; Lasanajak Y; Smith DF; Song X; Hossain MS; Owonikoko TK -
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Clin Lung Cancer Volume: 23 Page(s): e400 - e404
11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S -
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
J Clin Invest Volume: 132
08/01/2022 Authors: Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F -
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Future Oncol Volume: 18 Page(s): 2639 - 2649
08/01/2022 Authors: Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK -
Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER-Medicare Database Analysis.
Cancers (Basel) Volume: 14
06/30/2022 Authors: Nazha B; Zhang C; Chen Z; Ragin C; Owonikoko TK -
A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Cancers (Basel) Volume: 14
05/26/2022 Authors: Bauman JE; Chen Z; Zhang C; Ohr JP; Ferris RL; McGorisk GM; Brandt S; Srivatsa S; Chen AY; Steuer CE -
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Cell Volume: 185 Page(s): 1974 - 1985.e12
05/26/2022 Authors: Mo X; Niu Q; Ivanov AA; Tsang YH; Tang C; Shu C; Li Q; Qian K; Wahafu A; Doyle SP -
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Clin Cancer Res Volume: 28 Page(s): 1540 - 1548
04/14/2022 Authors: Meric-Bernstam F; Tannir NM; Iliopoulos O; Lee RJ; Telli ML; Fan AC; DeMichele A; Haas NB; Patel MR; Harding JJ -
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.
J Immunother Cancer Volume: 10
04/01/2022 Authors: Kang Y-K; Reck M; Nghiem P; Feng Y; Plautz G; Kim HR; Owonikoko TK; Boku N; Chen L-T; Lei M -
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
Oncogene Volume: 41 Page(s): 1691 - 1700
03/01/2022 Authors: Ma G; Deng Y; Qian L; Vallega KA; Zhang G; Deng X; Owonikoko TK; Ramalingam SS; Fang DD; Zhai Y -
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
Oncogene Volume: 40 Page(s): 6653 - 6665
12/01/2021 Authors: Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun S-Y -
Physician Communication and Patient Understanding of Molecular Testing Terminology.
Oncologist Volume: 26 Page(s): 934 - 940
11/01/2021 Authors: Blee SM; Shah RP; Pinheiro APM; Switchenko J; Dixon M; Owonikoko TK; Hill CE; Szabo SM; Pentz RD -
Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Adv Ther Volume: 38 Page(s): 5431 - 5451
11/01/2021 Authors: Das M; Padda SK; Weiss J; Owonikoko TK -
NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys Volume: 111 Page(s): e470 - e471
11/01/2021 Authors: Higgins KA; Hu C; Stinchcombe TE; Jabbour SK; Kozono DE; Owonikoko TK; Movsas B; Ritter TA; Xiao C; Williams TM -
Feasibility of Using FDG in the Stereotactic Ablative Setting for Tracked Dose Delivery With BgRT: Results from a Prospective Study of Serial Inter-Fraction PET/CTs.
Int J Radiat Oncol Biol Phys Volume: 111 Page(s): S97
11/01/2021 Authors: Da Silva A; Olcott P; Tian S; Yang X; Sethi I; Shirvani SM; Mazin S; Owonikoko TK; Bradley JD; Schuster DM -
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Mol Cancer Res Volume: 19 Page(s): 1622 - 1634
10/01/2021 Authors: Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK -
Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials.
Psychooncology Volume: 30 Page(s): 1739 - 1744
10/01/2021 Authors: Hianik RS; Owonikoko T; Switchenko J; Dixon MD; Shaib WL; Pentz RD -
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Cancer Res Volume: 81 Page(s): 4822 - 4834
09/15/2021 Authors: Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD-Y; Wang Q; He Y; Owonikoko TK -
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Oncologist Volume: 26 Page(s): e1508 - e1513
09/01/2021 Authors: Babiker H; Brana I; Mahadevan D; Owonikoko T; Calvo E; Rischin D; Moreno V; Papadopoulos KP; Crittenden M; Formenti S -
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Nave Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Clin Cancer Res Volume: 27 Page(s): 3884 - 3895
07/15/2021 Authors: Byers LA; Bentsion D; Gans S; Penkov K; Son C; Sibille A; Owonikoko TK; Groen HJM; Gay CM; Fujimoto J -
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.
Cancer Chemother Pharmacol Volume: 87 Page(s): 689 - 700
05/01/2021 Authors: Li C; Hart L; Owonikoko TK; Aljumaily R; Rocha Lima CM; Conkling PR; Webb RT; Jotte RM; Schuster S; Edenfield WJ -
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Clin Lung Cancer Volume: 22 Page(s): 187 - 194.e1
05/01/2021 Authors: Owonikoko TK; Redman MW; Byers LA; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Al Baghdadi T -
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
J Clin Oncol Volume: 39 Page(s): 1349 - 1359
04/20/2021 Authors: Owonikoko TK; Park K; Govindan R; Ready N; Reck M; Peters S; Dakhil SR; Navarro A; Rodrguez-Cid J; Schenker M -
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer.
Eur J Cancer Volume: 147 Page(s): 51 - 57
04/01/2021 Authors: Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Wirth LJ -
An expanded universe of cancer targets.
Cell Volume: 184 Page(s): 1142 - 1155
03/04/2021 Authors: Hahn WC; Bader JS; Braun TP; Califano A; Clemons PA; Druker BJ; Ewald AJ; Fu H; Jagu S; Kemp CJ -
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.
Future Oncol Volume: 17 Page(s): 965 - 977
03/01/2021 Authors: Nazha B; Yang JC-H; Owonikoko TK -
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
J Thorac Oncol Volume: 16 Page(s): 464 - 476
03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR -
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer.
Clin Transl Sci Volume: 14 Page(s): 664 - 670
03/01/2021 Authors: Goldman JW; Barve M; Patel JD; Wozniak A; Dowlati A; Starodub A; Owonikoko TK; Edenfield W; Laurie SA; Da Costa D -
Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Oncotarget Volume: 12 Page(s): 251 - 252
02/02/2021 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer.
Cancer Discov Volume: 11 Page(s): 240 - 244
02/01/2021 Authors: Thomas PL; Madubata CJ; Aldrich MC; Lee MM; Owonikoko TK; Minna JD; Rudin CM; Sage J; Lovly CM -
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.
PLoS One Volume: 16 Page(s): e0254125
01/01/2021 Authors: Huang L; Bommireddy R; Munoz LE; Guin RN; Wei C; Ruggieri A; Menon AP; Li X; Shanmugam M; Owonikoko TK -
Discovery of Small Molecule Bak Activator for Lung Cancer Therapy.
Theranostics Volume: 11 Page(s): 8500 - 8516
01/01/2021 Authors: Park D; Anisuzzaman ASM; Magis AT; Chen G; Xie M; Zhang G; Behera M; Sica GL; Ramalingam SS; Owonikoko TK -
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
Theranostics Volume: 11 Page(s): 3964 - 3980
01/01/2021 Authors: Zhang S; Chen Z; Shi P; Fan S; He Y; Wang Q; Li Y; Ramalingam SS; Owonikoko TK; Sun S-Y -
Optimum health and inhibition of cancer progression by microbiome and resveratrol.
Front Biosci (Landmark Ed) Volume: 26 Page(s): 496 - 517
01/01/2021 Authors: Stokes Iii J; Vinayak S; Williams J; Malik S; Singh R; Manne U; Owonikoko TK; Mishra MK -
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Adv Ther Volume: 38 Page(s): 350 - 365
01/01/2021 Authors: Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK -
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.
Cancer Volume: 126 Page(s): 5040 - 5049
12/01/2020 Authors: Nazha B; Goyal S; Chen Z; Engelhart A; Carlisle JW; Beardslee TJ; Gill H; Odikadze L; Liu Y; Mishra MK -
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib.
Lung Cancer Volume: 150 Page(s): 26 - 35
12/01/2020 Authors: Gu J; Qian L; Zhang G; Mahajan NP; Owonikoko TK; Ramalingam SS; Sun S-Y -
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
J Immunother Cancer Volume: 8
12/01/2020 Authors: Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B -
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer (MTC)
Page(s): 7S - 8S
11/18/2020 Authors: Shah M; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Leboulleux S; Godbert Y -
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
Clin Cancer Res Volume: 26 Page(s): 5860 - 5868
11/15/2020 Authors: Shin DM; Nannapaneni S; Patel MR; Shi Q; Liu Y; Chen Z; Chen AY; El-Deiry MW; Beitler JJ; Steuer CE -
Simultaneous Integrated Boost of Lung Tumors in the Stereotactic Ablative Setting using BgRT Tracked Delivery
Volume: 108 Page(s): E306 - E306
11/01/2020 Authors: Olcott P; Shirvani SM; Tian S; Sethi I; Yang X; Da Silva A; Huntzinger C; Mazin S; Owonikoko TK; Schuster DM -
Increased 18F-FDG Metabolic Activity during Lung SBRT Predicts Risk of Disease Progression: Results from a Prospective Study of Serial Inter-Fraction PET/CTs
Volume: 108 Page(s): S59 - S60
11/01/2020 Authors: Tian S; Switchenko J; Yang X; Sethi I; Da Silva A; Huntzinger C; Shirvani S; Owonikoko TK; Schuster DM; Curran WJ -
An update on the immune landscape in lung and head and neck cancers.
CA Cancer J Clin Volume: 70 Page(s): 505 - 517
11/01/2020 Authors: Carlisle JW; Steuer CE; Owonikoko TK; Saba NF -
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA -
Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer.
Oncologist Volume: 25 Page(s): e1586 - e1588
10/01/2020 Authors: Langston AA; Quest TE; Abernethy ER; Campbell GP; Owonikoko TK; Pentz RD -
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial.
Cancer Med Volume: 9 Page(s): 7511 - 7523
10/01/2020 Authors: Steffen McLouth LE; Zhao F; Owonikoko TK; Feliciano JL; Mohindra NA; Dahlberg SE; Wade JL; Srkalovic G; Lash BW; Leach JW -
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
J Immunother Cancer Volume: 8
10/01/2020 Authors: Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC -
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Int J Radiat Oncol Biol Phys Volume: 108 Page(s): 304 - 313
09/01/2020 Authors: Tian S; Switchenko JM; Buchwald ZS; Patel PR; Shelton JW; Kahn SE; Pillai RN; Steuer CE; Owonikoko TK; Behera M -
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
N Engl J Med Volume: 383 Page(s): 825 - 835
08/27/2020 Authors: Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S -
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
Cancer Volume: 126 Page(s): 3788 - 3799
08/15/2020 Authors: Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun S-Y -
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q.
Cancer Volume: 126 Page(s): 3140 - 3150
07/01/2020 Authors: Pedro B; Rupji M; Dwivedi B; Kowalski J; Konen JM; Owonikoko TK; Ramalingam SS; Vertino PM; Marcus AI -
Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
J Biol Chem Volume: 295 Page(s): 8870
06/26/2020 Authors: Oh Y-T; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun S-Y -
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
Oncologist Volume: 25 Page(s): e964 - e975
06/01/2020 Authors: Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S -
EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Oncogene Volume: 39 Page(s): 4798 - 4813
06/01/2020 Authors: Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J -
BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.
Cancer Res Volume: 80 Page(s): 2380 - 2393
06/01/2020 Authors: Zong D; Gu J; Cavalcante GC; Yao W; Zhang G; Wang S; Owonikoko TK; He X; Sun S-Y -
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA -
Integrating Genetic and Genomic Testing Into Oncology Practice.
Am Soc Clin Oncol Educ Book Volume: 40 Page(s): e259 - e263
05/01/2020 Authors: Domchek SM; Mardis E; Carlisle JW; Owonikoko TK -
New Approaches to SCLC Therapy: From the Laboratory to the Clinic.
J Thorac Oncol Volume: 15 Page(s): 520 - 540
04/01/2020 Authors: Poirier JT; George J; Owonikoko TK; Berns A; Brambilla E; Byers LA; Carbone D; Chen HJ; Christensen CL; Dive C -
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
Mol Oncol Volume: 14 Page(s): 882 - 895
04/01/2020 Authors: Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun S-Y -
Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.
Head Neck Volume: 42 Page(s): 678 - 687
04/01/2020 Authors: Tian S; Switchenko JM; Fei T; Press RH; Abugideiri M; Saba NF; Owonikoko TK; Chen AY; Beitler JJ; Curran WJ -
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Cancer Volume: 126 Page(s): 1339 - 1350
03/15/2020 Authors: Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun S-Y -
Association Between PD-L1 Expression and c-Met Alterations in Non-Small Cell Lung Carcinoma
Volume: 33 Page(s): 1821 - 1821
03/01/2020 Authors: Tenney T; Sica G; Saxe D; Owonikoko T; Ramalingam S; Zhang L -
Association Between PD-L1 Expression and c-Met Alterations in Non-Small Cell Lung Carcinoma
Volume: 100 Page(s): 1821 - 1821
03/01/2020 Authors: Tenney T; Sica G; Saxe D; Owonikoko T; Ramalingam S; Zhang L -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist Volume: 25 Page(s): e528 - e535
03/01/2020 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials.
Cancer Volume: 126 Page(s): 575 - 582
02/01/2020 Authors: Martini DJ; Kline MR; Liu Y; Shabto JM; Williams MA; Khan AI; Lewis C; Collins H; Akce M; Kissick HT -
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
J Thorac Oncol Volume: 15 Page(s): 274 - 287
02/01/2020 Authors: Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC -
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.
Front Oncol Volume: 10 Page(s): 1000
01/01/2020 Authors: Nazha B; Inal C; Owonikoko TK -
The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.
Am J Cancer Res Volume: 10 Page(s): 3316 - 3327
01/01/2020 Authors: Yu D; Li Y; Sun KD; Gu J; Chen Z; Owonikoko TK; Ramalingam SS; Sun S-Y -
Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma.
Case Rep Oncol Volume: 13 Page(s): 239 - 244
01/01/2020 Authors: Zakka K; Zakka P; Davarpanah A; Koshkelashvili N; Bilen MA; Owonikoko T; El-Rayes B; Akce M -
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Cancer Volume: 126 Page(s): 2024 - 2033
01/01/2020 Authors: Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun S-Y -
Mcl-1 Interacts with Akt to Promote Lung Cancer Progression.
Cancer Res Volume: 79 Page(s): 6126 - 6138
12/15/2019 Authors: Chen G; Park D; Magis AT; Behera M; Ramalingam SS; Owonikoko TK; Sica GL; Ye K; Zhang C; Chen Z -
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.
Oncologist
12/05/2019 Authors: Bilen MA; Martini DJ; Liu Y; Shabto JM; Brown JT; Williams M; Khan AI; Speak A; Lewis C; Collins H -
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Invest New Drugs Volume: 37 Page(s): 1198 - 1206
12/01/2019 Authors: Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL -
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Cancer Chemother Pharmacol Volume: 84 Page(s): 1289 - 1301
12/01/2019 Authors: Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R -
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: APropensity Score-Matched Analysis of the National Cancer Database.
Clin Lung Cancer Volume: 20 Page(s): 484 - 493.e6
11/01/2019 Authors: Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP -
The Presence of Secondary Follicles in Early Stage Lung Adenocarcinoma Reflects Disease Burden
Volume: 14 Page(s): S1146 - S1146
11/01/2019 Authors: Obeng R; Behera M; Owonikoko T; Pillai R; Ahmed R; Ramalingam S; Sica G -
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Clin Cancer Res Volume: 25 Page(s): 6119 - 6126
10/15/2019 Authors: Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK -
Analysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials
Volume: 30 Page(s): 486 - 486
10/01/2019 Authors: Reck M; Feng Y; Kim HR; Plautz G; Kang Y-K; Owonikoko TK; Nghiem P; Sheng J -
Lung Stereotactic Body Radiotherapy and Concurrent Immunotherapy: A Multi-Center Safety and Toxicity Analysis
Volume: 14 Page(s): S248 - S248
10/01/2019 Authors: Tian S; Switchenko J; Patel P; Shelton J; Kahn S; Pillai R; Steuer C; Owonikoko T; Behera M; Curran W -
Impact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
Volume: 30 Page(s): 756 - 756
10/01/2019 Authors: Tahara M; Kiyota N; Hoff AO; Badiu C; Owonikoko TK; Dutcus CE; Suzuki T; Ren M; Misir S; Wirth LJ -
Integration of Durvalumab into the Treatment of Stage III Non-Small Cell Lung Cancer: Real-World Considerations
Volume: 14 Page(s): S588 - S589
10/01/2019 Authors: Gorgens S; Schreibmann E; Behera M; Steuer C; Pillai R; Owonikoko T; Shelton J; Ramalingam S; Curran W; Higgins K -
Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors
Volume: 14 Page(s): S445 - S446
10/01/2019 Authors: Whisenant J; Beckermann K; Borghaei H; Owonikoko T; Patel J; Berry L; Shyr Y; Harrow K; Liang C; Holzhausen A -
Inter-Fraction Variability of 18-FDG PET During Lung SBRT and the Effect of Systemic and Immunotherapy: Results of a Prospective Pilot Study
Volume: 14 Page(s): S607 - S608
10/01/2019 Authors: Tian S; Switchenko J; Sethi I; Yang X; Da Silva A; Owonikoko T; Schuster D; Curran W; Higgins K -
NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab in LS-SCLC
Volume: 14 Page(s): S821 - S821
10/01/2019 Authors: Higgins K; Hu C; Ross H; Jabbour S; Kozono D; Owonikoko T; Movsas B; Xiao C; Solberg T; Williams T -
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Ann Oncol Volume: 30 Page(s): 1613 - 1621
10/01/2019 Authors: Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV -
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.
J Clin Invest Volume: 129 Page(s): 4110 - 4123
10/01/2019 Authors: Pan C; Chun J; Li D; Boese AC; Li J; Kang J; Umano A; Jiang Y; Song L; Magliocca KR -
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
BMC Cancer Volume: 19 Page(s): 857
08/29/2019 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL -
The Immune Landscape of Cancer.
Immunity Volume: 51 Page(s): 411 - 412
08/20/2019 Authors: Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA -
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced -TrCP degradation.
Oncogene Volume: 38 Page(s): 6270 - 6282
08/01/2019 Authors: Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun S-Y -
Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors
Volume: 79
07/01/2019 Authors: Whisenant JG; Beckerman K; Borghaei H; Owonikoko T; Patel J; Shyr Y; Harrow K; Liang C; Holzhausen A; Wakelee H -
Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.
Volume: 37
05/20/2019 Authors: Hart LL; Andric ZG; Hussein MA; Ferrarotto R; Beck JT; Subramanian J; Radosavljevic DZ; Jovanovic D; Pachipala KK; Samarzija M -
Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).
Volume: 37
05/20/2019 Authors: Smit M-AD; Borghaei H; Owonikoko TK; Hummel H-D; Johnson ML; Champiat S; Salgia R; Udagawa H; Boyer MJ; Govindan R -
Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.
Volume: 37
05/20/2019 Authors: Nazha B; Chen Z; Goyal S; Engelhart A; Carlisle JW; Beardslee T; Gill H; Odikadze L; Liu Y; Mishra MK -
Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.
Volume: 37
05/20/2019 Authors: Shin DM; Beitler JJ; El-Deiry M; Steuer CE; Chen AY; Baddour HM; Chen ZG; Roser S; Magliocca KR; Patel M -
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
Volume: 37
05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G -
Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance.
J Clin Invest Volume: 129 Page(s): 2431 - 2445
05/13/2019 Authors: Pan C; Jin L; Wang X; Li Y; Chun J; Boese AC; Li D; Kang H-B; Zhang G; Zhou L -
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
Volume: 41 Page(s): 1490 - 1498
05/01/2019 Authors: Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R -
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
J Thorac Oncol Volume: 14 Page(s): 876 - 889
05/01/2019 Authors: El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ -
The clinical conundrum of managing relapsed small cell lung cancer.
Cancer Volume: 125 Page(s): 1022 - 1026
04/01/2019 Authors: Nazha B; Owonikoko TK -
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study.
Volume: 30 Suppl 2 Page(s): ii77
04/01/2019 Authors: Owonikoko TK; Kim HR; Govindan R; Ready N; Reck M; Peters S; Dakhil SR; Navarro A; Rodriguez-Cid J; Schenker M -
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
Am J Clin Oncol Volume: 42 Page(s): 331 - 336
04/01/2019 Authors: Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D -
Sequential immunotherapy and association with clinical outcomes in advanced-stage cancer patients
Volume: 7
02/01/2019 Authors: Bilen M; Martini D; Liu Y; Lewis C; Collins H; Shabto J; Akce M; Kissick H; Carthon B; Shaib W -
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study.
J Clin Oncol Volume: 37 Page(s): 222 - 229
01/20/2019 Authors: Owonikoko TK; Dahlberg SE; Sica GL; Wagner LI; Wade JL; Srkalovic G; Lash BW; Leach JW; Leal TB; Aggarwal C -
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
PLoS One Volume: 14 Page(s): e0206309
01/01/2019 Authors: Owonikoko TK; Zhang G; Lallani SB; Chen Z; Martinson DE; Khuri FR; Lonial S; Marcus A; Sun S-Y -
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Cancer Volume: 125 Page(s): 127 - 134
01/01/2019 Authors: Bilen MA; Martini DJ; Liu Y; Lewis C; Collins HH; Shabto JM; Akce M; Kissick HT; Carthon BC; Shaib WL -
Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy.
Am Soc Clin Oncol Educ Book Volume: 39 Page(s): 3 - 10
01/01/2019 Authors: Nazha B; Mishra M; Pentz R; Owonikoko TK -
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Volume: 29 Page(s): 27 - 27
12/01/2018 Authors: Babiker HM; Brana I; Mahadevan D; Owonikoko TK; Calvo E; Rischin D; Moreno V; Papadopoulos KP; Crittenden M; Formenti S -
Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
Volume: 102 Page(s): E27 - E27
11/01/2018 Authors: Saba NF; Force S; Staley CA; Fernandez F; Willingham FF; Pickens A; Cardona K; Chen Z; Goff L; Cardin D -
Survival Advantage to Combined Modality Therapy Seen in Multiple Subgroups Within Anaplastic Thyroid Carcinoma: A Propensity-Score Matched Analysis of the National Cancer Data Base
Volume: 102 Page(s): E356 - E357
11/01/2018 Authors: Tian S; Switchenko J; Fei T; Press RH; Abugideiri M; Saba NF; Owonikoko TK; Chen AY; Beitler JJ; Curran WJ -
Report of Neurotoxicity after Concurrent Whole Brain Radiation Therapy and Checkpoint Blockade Immunotherapy for Patients with Brain Metastases
Volume: 102 Page(s): E340 - E340
11/01/2018 Authors: Press RH; Buchwald ZS; Steuer C; Pillai R; Owonikoko TK; Ramalingam S; Curran WJ; Higgins KA -
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Cell Rep Volume: 25 Page(s): 1304 - 1317.e5
10/30/2018 Authors: Wang Y; Xu X; Maglic D; Dill MT; Mojumdar K; Ng PK-S; Jeong KJ; Tsang YH; Moreno D; Bhavana VH -
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- Superfamily.
Cell Syst Volume: 7 Page(s): 422 - 437.e7
10/24/2018 Authors: Korkut A; Zaidi S; Kanchi RS; Rao S; Gough NR; Schultz A; Li X; Lorenzi PL; Berger AC; Robertson G -
Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy.
Volume: 29 Suppl 8 Page(s): viii597
10/01/2018 Authors: Dragnev KH; Owonikoko TK; Csoszi T; Maglakelidze M; Beck JT; Domine Gomez M; Lowczak A; Fulop A; Hoyer RJ; Hanna W -
Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy.
Volume: 29 Suppl 8 Page(s): viii598
10/01/2018 Authors: Sorrentino JA; Lai A; Weiss JM; Dragnev KH; Owonikoko TK; Adler S; Antal JM; Malik RK; Roberts PJ -
Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Volume: 29 Suppl 8 Page(s): viii42
10/01/2018 Authors: Bilen MA; Martini DJ; Shabto JM; Liu Y; Khan AI; Williams MA; Lewis C; Collins HH; Kissick H; Carthon BC -
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data.
Volume: 29 Suppl 8 Page(s): viii461 - viii462
10/01/2018 Authors: Owonikoko TK; Papadopoulos KP; Gil-Martin M; Moreno V; Salama AK; Calvo E; Safran H; Gonzlez-Martn A; Aljumaily R; Mahadevan D -
Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Volume: 29 Suppl 8 Page(s): viii418
10/01/2018 Authors: Babiker HM; Brana I; Mahadevan D; Owonikoko TK; Calvo E; Rischin D; Moreno V; Papadopoulos KP; Crittenden M; Formenti S -
SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
Volume: 13 Page(s): S972 - S972
10/01/2018 Authors: Owonikoko T; Dahlberg S; Sica G; Poirier J; Byers L; Rudin C; Wistuba I; Ramalingam S -
Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).
Ann Oncol Volume: 29 Suppl 8 Page(s): viii433
10/01/2018 Authors: Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins HH; Akce M; Kissick H; Carthon BC; Shaib WL -
REGN2810, a fully human programmed death protein 1 (PD-1) monoclonal antibody for unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Updated follow-up of patients treated in a phase I study
Volume: 79 Page(s): AB243 - AB243
09/01/2018 Authors: Papadopoulos K; Owonikoko T; Johnson M; Yee N; Safran H; Mohan K; Emeremni C; Stankevich E; Lowy I; Fury M -
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Cancer Volume: 124 Page(s): 3586 - 3595
09/01/2018 Authors: Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS -
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
Cancer Cell Volume: 34 Page(s): 211 - 224.e6
08/13/2018 Authors: Kahles A; Lehmann K-V; Toussaint NC; Hser M; Stark SG; Sachsenberg T; Stegle O; Kohlbacher O; Sander C; Cancer Genome Atlas Research Network -
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Cancer Cell Volume: 34 Page(s): 315 - 330.e7
08/13/2018 Authors: Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang H-B; Song L; Wang D -
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
J Clin Oncol Volume: 36 Page(s): 2386 - 2394
08/10/2018 Authors: Pietanza MC; Waqar SN; Krug LM; Dowlati A; Hann CL; Chiappori A; Owonikoko TK; Woo KM; Cardnell RJ; Fujimoto J -
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell Volume: 174 Page(s): 1034 - 1035
08/09/2018 Authors: Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B -
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med Volume: 379 Page(s): 341 - 351
07/26/2018 Authors: Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS -
Targeting Mcl-1 enhances DNA replication stress sensitivity for cancer therapy
Volume: 78
07/01/2018 Authors: Chen G; Magis A; Xu K; Park D; Yu D; Owonikoko T; Sica G; Satola S; Ramalingam S; Curran W -
Blood based biomarkers and association with clinical outcome (CO) in advanced stage patients (pts) treated with immunotherapy (IO)
Volume: 78
07/01/2018 Authors: Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai R -
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Cell Rep Volume: 23 Page(s): 3698
06/19/2018 Authors: Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R -
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
Volume: 36
05/20/2018 Authors: Owonikoko TK; Papadopoulos KP; Johnson ML; Martin MG; Moreno V; Salama AKS; Calvo E; Yee NS; Safran H; Gonzalez-Martin A -
Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
Volume: 36
05/20/2018 Authors: Subbiah V; Cascone T; Hess KR; Subbiah IM; Nelson S; Morikawa N; Nilsson MB; Bhatt T; Ali S; William WN -
Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer.
Volume: 36
05/20/2018 Authors: Gupta D; Liu Y; Jiang R; Fernandez F; Force S; Pickens A; Steuer CE; McDonald MW; Higgins KA; Beitler JJ -
Safety and efficacy of combining pembrolizmumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.
Volume: 36
05/20/2018 Authors: Khan MK; Nasti T; Masoumy L; Kamphorst AO; Yushak MI; Owonikoko TK; Kudchadkar RR; Ramalingam SS; Lawson DH; Ahmed R -
Prevalence and prognosis of DNA repair deficiency in squamous cell carcinoma (SCC) patients enrolled on the S1400 LungMAP study.
Volume: 36
05/20/2018 Authors: Owonikoko TK; Redman MW; Byers LA; Griffin K; Hirsch FR; Mack PC; Gandara DR; Bradley JD; Stinchcombe T; Kelly K -
Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO)
Volume: 36
05/20/2018 Authors: Martini DJ; Liu Y; Lewis CM; Shabto JM; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Pillai RN -
The Immune Landscape of Cancer.
Immunity Volume: 48 Page(s): 812 - 830.e14
04/17/2018 Authors: Thorsson V; Gibbs DL; Brown SD; Wolf D; Bortone DS; Ou Yang T-H; Porta-Pardo E; Gao GF; Plaisier CL; Eddy JA -
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
Cancer Cell Volume: 33 Page(s): 690 - 705.e9
04/09/2018 Authors: Berger AC; Korkut A; Kanchi RS; Hegde AM; Lenoir W; Liu W; Liu Y; Fan H; Shen H; Ravikumar V -
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
Cancer Cell Volume: 33 Page(s): 721 - 735.e8
04/09/2018 Authors: Liu Y; Sethi NS; Hinoue T; Schneider BG; Cherniack AD; Sanchez-Vega F; Seoane JA; Farshidfar F; Bowlby R; Islam M -
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
Cancer Cell Volume: 33 Page(s): 706 - 720.e9
04/09/2018 Authors: Wang Z; Yang B; Zhang M; Guo W; Wu Z; Wang Y; Jia L; Li S; Cancer Genome Atlas Research Network; Xie W -
Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
Cancer Cell Volume: 33 Page(s): 676 - 689.e3
04/09/2018 Authors: Taylor AM; Shih J; Ha G; Gao GF; Zhang X; Berger AC; Schumacher SE; Wang C; Hu H; Liu J -
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Cell Volume: 173 Page(s): 305 - 320.e10
04/05/2018 Authors: Ding L; Bailey MH; Porta-Pardo E; Thorsson V; Colaprico A; Bertrand D; Gibbs DL; Weerasinghe A; Huang K-L; Tokheim C -
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
Cell Volume: 173 Page(s): 291 - 304.e6
04/05/2018 Authors: Hoadley KA; Yau C; Hinoue T; Wolf DM; Lazar AJ; Drill E; Shen R; Taylor AM; Cherniack AD; Thorsson V -
Pathogenic Germline Variants in 10,389 Adult Cancers.
Cell Volume: 173 Page(s): 355 - 370.e14
04/05/2018 Authors: Huang K-L; Mashl RJ; Wu Y; Ritter DI; Wang J; Oh C; Paczkowska M; Reynolds S; Wyczalkowski MA; Oak N -
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
Cell Volume: 173 Page(s): 386 - 399.e12
04/05/2018 Authors: Chen H; Li C; Peng X; Zhou Z; Weinstein JN; Cancer Genome Atlas Research Network; Liang H -
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
Cell Volume: 173 Page(s): 338 - 354.e15
04/05/2018 Authors: Malta TM; Sokolov A; Gentles AJ; Burzykowski T; Poisson L; Weinstein JN; Kamiska B; Huelsken J; Omberg L; Gevaert O -
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Cell Volume: 173 Page(s): 321 - 337.e10
04/05/2018 Authors: Sanchez-Vega F; Mina M; Armenia J; Chatila WK; Luna A; La KC; Dimitriadoy S; Liu DL; Kantheti HS; Saghafinia S -
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
Cell Volume: 173 Page(s): 400 - 416.e11
04/05/2018 Authors: Liu J; Lichtenberg T; Hoadley KA; Poisson LM; Lazar AJ; Cherniack AD; Kovatich AJ; Benz CC; Levine DA; Lee AV -
Comprehensive Characterization of Cancer Driver Genes and Mutations.
Cell Volume: 173 Page(s): 371 - 385.e18
04/05/2018 Authors: Bailey MH; Tokheim C; Porta-Pardo E; Sengupta S; Bertrand D; Weerasinghe A; Colaprico A; Wendl MC; Kim J; Reardon B -
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Cell Rep Volume: 23 Page(s): 172 - 180.e3
04/03/2018 Authors: Way GP; Sanchez-Vega F; La K; Armenia J; Chatila WK; Luna A; Sander C; Cherniack AD; Mina M; Ciriello G -
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
Cell Rep Volume: 23 Page(s): 213 - 226.e3
04/03/2018 Authors: Ge Z; Leighton JS; Wang Y; Peng X; Chen Z; Chen H; Sun Y; Yao F; Li J; Zhang H -
Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
Cell Rep Volume: 23 Page(s): 282 - 296.e4
04/03/2018 Authors: Seiler M; Peng S; Agrawal AA; Palacino J; Teng T; Zhu P; Smith PG; Cancer Genome Atlas Research Network; Buonamici S; Yu L -
Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
Cell Rep Volume: 23 Page(s): 270 - 281.e3
04/03/2018 Authors: Jayasinghe RG; Cao S; Gao Q; Wendl MC; Vo NS; Reynolds SM; Zhao Y; Climente-Gonzlez H; Chai S; Wang F -
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
Cell Rep Volume: 23 Page(s): 194 - 212.e6
04/03/2018 Authors: Campbell JD; Yau C; Bowlby R; Liu Y; Brennan K; Fan H; Taylor AM; Wang C; Walter V; Akbani R -
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
Cell Rep Volume: 23 Page(s): 255 - 269.e4
04/03/2018 Authors: Peng X; Chen Z; Farshidfar F; Xu X; Lorenzi PL; Wang Y; Cheng F; Tan L; Mojumdar K; Du D -
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Cell Rep Volume: 23 Page(s): 227 - 238.e3
04/03/2018 Authors: Gao Q; Liang W-W; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao W-W; Reynolds SM; Wyczalkowski MA; Yao L -
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
Cell Rep Volume: 23 Page(s): 297 - 312.e12
04/03/2018 Authors: Chiu H-S; Somvanshi S; Patel E; Chen T-W; Singh VP; Zorman B; Patil SL; Pan Y; Chatterjee SS; Cancer Genome Atlas Research Network -
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Cell Rep Volume: 23 Page(s): 239 - 254.e6
04/03/2018 Authors: Knijnenburg TA; Wang L; Zimmermann MT; Chambwe N; Gao GF; Cherniack AD; Fan H; Shen H; Way GP; Greene CS -
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Cell Rep Volume: 23 Page(s): 313 - 326.e5
04/03/2018 Authors: Ricketts CJ; De Cubas AA; Fan H; Smith CC; Lang M; Reznik E; Bowlby R; Gibb EA; Akbani R; Beroukhim R -
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.
Cell Rep Volume: 23 Page(s): 181 - 193.e7
04/03/2018 Authors: Saltz J; Gupta R; Hou L; Kurc T; Singh P; Nguyen V; Samaras D; Shroyer KR; Zhao T; Batiste R -
Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung.
Volume: 126 Page(s): 236 - 242
04/01/2018 Authors: Hanley KZ; Dureau ZJ; Cohen C; Shin DM; Owonikoko TK; Sica GL -
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.
Cell Syst Volume: 6 Page(s): 271 - 281.e7
03/28/2018 Authors: Ellrott K; Bailey MH; Saksena G; Covington KR; Kandoth C; Stewart C; Hess J; Ma S; Chiotti KE; McLellan M -
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Cell Syst Volume: 6 Page(s): 282 - 300.e2
03/28/2018 Authors: Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y -
A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
Mol Cancer Ther Volume: 17 Page(s): 710 - 716
03/01/2018 Authors: Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM -
Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
Cancer Volume: 124 Page(s): 775 - 784
02/15/2018 Authors: Cassidy RJ; Zhang X; Switchenko JM; Patel PR; Shelton JW; Tian S; Nanda RH; Steuer CE; Pillai RN; Owonikoko TK -
The Integrated Genomic Landscape of Thymic Epithelial Tumors.
Cancer Cell Volume: 33 Page(s): 244 - 258.e10
02/12/2018 Authors: Radovich M; Pickering CR; Felau I; Ha G; Zhang H; Jo H; Hoadley KA; Anur P; Zhang J; McLellan M -
Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)-Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
Volume: 36
02/10/2018 Authors: Papadopoulos KP; Owonikoko TK; Johnson M; Brana I; Martin MG; Perez RP; Moreno V; Salama AK; Calvo E; Yee NS -
Immunotherapy of lung cancer.
J Thorac Dis Volume: 10 Page(s): S395 - S396
02/01/2018 Authors: Owonikoko TK; Borghaei H -
Immune checkpoint inhibitors in small cell lung cancer.
J Thorac Dis Volume: 10 Page(s): S460 - S467
02/01/2018 Authors: Pakkala S; Owonikoko TK -
Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer
Volume: 78
02/01/2018 Authors: Kalinsky K; Harding JJ; DeMichele A; Infante JR; Gogineni K; Owonikoko TK; Isakoff S; Iliopoulos O; Patel MR; Munster P -
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Cancer Volume: 124 Page(s): 271 - 277
01/15/2018 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS -
The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer.
Mol Cell Volume: 69 Page(s): 87 - 99.e7
01/04/2018 Authors: Jin L; Chun J; Pan C; Kumar A; Zhang G; Ha Y; Li D; Alesi GN; Kang Y; Zhou L -
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy.
J Clin Invest Volume: 128 Page(s): 500 - 516
01/02/2018 Authors: Chen G; Magis AT; Xu K; Park D; Yu DS; Owonikoko TK; Sica GL; Satola SW; Ramalingam SS; Curran WJ -
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.
Oncology Volume: 95 Page(s): 138 - 146
01/01/2018 Authors: Owonikoko TK; Busari AK; Kim S; Chen Z; Akintayo A; Lewis C; Carthon BC; Alese OB; El-Rayes BF; Ramalingam SS -
Clinical activity of adenosine 2A receptor (A2AR) inhibitor CPI-444 is associated with tumor expression of adenosine pathway genes and tumor immune modulation
Volume: 5
11/07/2017 Authors: Hotson A; Powderly J; Emens L; Forde P; Hellman M; Fong L; Markman B; Hughes B; Goldman J; Sznol M -
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
Cell Volume: 171 Page(s): 950 - 965.e28
11/02/2017 Authors: Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network -
Utilization of PET Scan in Advanced Stage Non-Small Cell Lung Cancer in the United States
Volume: 12 Page(s): S2325 - S2326
11/01/2017 Authors: Behera M; Jiang R; Higgins K; Pillai R; Owonikoko T; Belani C; Khuri F; Ward K; Curran W; Ramalingam S -
Exploratory Analysis for Predictors of Benefit of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
Volume: 12 Page(s): S1766 - S1767
11/01/2017 Authors: Owonikoko T; Dahlberg S; Poirier J; Sica G; Rudin C; Ramalingam S -
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
Volume: 12 Page(s): S2013 - S2014
11/01/2017 Authors: Higgins K; Pillai R; Chen Z; Zhang C; Patel P; Pakkala S; Shelton J; Force S; Fernandez F; Steuer C -
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
J Thorac Oncol Volume: 12 Page(s): 1687 - 1695
11/01/2017 Authors: Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG -
Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Clin Lung Cancer Volume: 18 Page(s): 706 - 718
11/01/2017 Authors: Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE -
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
Clin Cancer Res Volume: 23 Page(s): 6567 - 6579
11/01/2017 Authors: Shi P; Oh Y-T; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E -
A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients.
Oncotarget Volume: 8 Page(s): 81441 - 81454
10/06/2017 Authors: Byers LA; Horn L; Ghandi J; Kloecker G; Owonikoko T; Waqar SN; Krzakowski M; Cardnell RJ; Fujimoto J; Taverna P -
Next Generation Sequencing and Clinical Outcomes of Lung Adenocarcinomas Treated With Stereotactic Body Radiation Therapy
Volume: 99 Page(s): S241 - S241
10/01/2017 Authors: Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer C; Pillai R -
KRAS Mutant Non-small Cell Lung Cancer is Associated With Increased Risk of Salvage Whole Brain Radiation after Stereotactic Radiosurgery for Brain Metastases
Volume: 99 Page(s): E100 - E101
10/01/2017 Authors: Press RH; Zhang X; Cassidy RJ; Ferris MJ; Zhong J; Steuer C; Pillai R; Owonikoko TK; Ramalingam S; Patel PR -
Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cancer Volume: 123 Page(s): 3681 - 3690
10/01/2017 Authors: Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN -
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
Cancer Volume: 123 Page(s): 3476 - 3485
09/15/2017 Authors: Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K -
Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis.
Clin Lung Cancer Volume: 18 Page(s): 551 - 558.e6
09/01/2017 Authors: Cassidy RJ; Patel PR; Zhang X; Press RH; Switchenko JM; Pillai RN; Owonikoko TK; Ramalingam SS; Fernandez FG; Force SD -
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.
Cancer Cell Volume: 32 Page(s): 185 - 203.e13
08/14/2017 Authors: Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network -
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
JAMA Oncol Volume: 3 Page(s): 1120 - 1129
08/01/2017 Authors: Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ -
Modulation of Bax and mTOR for cancer therapeutics
Volume: 77
07/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W -
Modulation of Bax and mTOR for Cancer Therapeutics.
Cancer Res Volume: 77 Page(s): 3001 - 3012
06/01/2017 Authors: Li R; Ding C; Zhang J; Xie M; Park D; Ding Y; Chen G; Zhang G; Gilbert-Ross M; Zhou W -
Presence of genetic aberrations in patients with brain metastases from non-small cell lung cancer (NSCLC) and clinical outcomes
Volume: 35
05/20/2017 Authors: Press RH; Zhang X; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Ramalingam SS; Patel PR -
REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)-Initial safety and efficacy from expansion cohorts (ECs) of phase I study.
Volume: 35
05/20/2017 Authors: Papadopoulos KP; Owonikoko TK; Johnson ML; Brana I; -Martin MG; Perez RP; Moreno V; Salama AK; Calvo E; Yee NS -
Optimal thoracic radiation dose in limited stage small cell lung cancer.
Volume: 35
05/20/2017 Authors: Behera M; Zhang X; Jiang R; Pillai RN; Patel PR; Pakkala S; Steuer CE; Saba NF; Owonikoko TK; Belani C -
Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.
Volume: 35
05/20/2017 Authors: Higgins KA; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP -
Enrollment into molecular selection trials and impact on patient disposition.
Volume: 35
05/20/2017 Authors: Harvey RD; Steuer CE; Judson EC; Lewis CM; Collins HH; Saba NF; El-Rayes BF; Curran WJ; Rannalingam SS; Pentz RD -
Small cell carcinoma of the head and neck: Incidence and survival trends based on the Surveillance and Epidemiologic and End Results (SEER) analysis.
Volume: 35
05/20/2017 Authors: Bean M; Goodman M; Steuer CE; Patel M; McDonald MW; Higgins KA; Owonikoko TK; Beitler JJ; Shin DM; Saba NF -
Institutional treatment volume and outcomes in salivary gland cancer.
Volume: 35
05/20/2017 Authors: Steuer CE; Switchenko JM; Griffith CC; Patel M; Cassidy RJ; Gillespie TW; McDonald MW; Higgins KA; Beitler JJ; Owonikoko TK -
Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
Volume: 35
05/20/2017 Authors: Saba NF; Force SD; Staley CA; Fernandez FG; Willingham FF; Allan P; Cardona K; Chen Z; Cardin DB; Lambright E -
Collection and utilization of oncology big data.
Volume: 35
05/20/2017 Authors: Pant S; Owonikoko TK; Diefenbach CSM; Kim S; Chen Z; Towle EL; Pierce LJ; Mileham KF -
Early proliferation of PD-1+CD8 T cells in peripheral blood as predictive of response to PD-1 inhibition for patients with advanced NSCLC
Volume: 35
05/20/2017 Authors: Pillai RN; Kamphorst A; Yang S; Owonikoko TK; Sica G; Nasti T; Akondy R; Wieland A; Wu H; Patel N -
Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC) -Phase 1b results.
Volume: 35
05/20/2017 Authors: Lima CMSR; Roberts PJ; Priego VM; Divers SG; Thomas MB; Boccia RV; Stabler K; Andrews E; Malik RK; Aljumaily R -
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Proc Natl Acad Sci U S A Volume: 114 Page(s): 4993 - 4998
05/09/2017 Authors: Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT -
Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer in Patients 80 Years and Older: A Multi-Center Analysis.
Int J Radiat Oncol Biol Phys Volume: 98 Page(s): 229 - 230
05/01/2017 Authors: Cassidy RJ; Patel PR; Zhang X; Press RH; Switchenko J; Pillai R; Owonikoko TK; Ramalingam S; Fernandez F; Force S -
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
Volume: 18 Page(s): 286 - 292
05/01/2017 Authors: Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK -
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
Volume: 355 Page(s): 1423 - 1427
03/31/2017 Authors: Kamphorst AO; Wieland A; Nasti T; Yang S; Zhang R; Barber DL; Konieczny BT; Daugherty CZ; Koenig L; Yu K -
Orthopedia Homeobox (OTP) Is Preferentially Expressed in Typical Carcinoids of the Lung
Volume: 30 Page(s): 94A - 94A
02/01/2017 Authors: Dureau Z; Sica G; Cohen C; Owonikoko TK; Hanley KZ -
Integrated genomic characterization of oesophageal carcinoma.
Nature Volume: 541 Page(s): 169 - 175
01/12/2017 Authors: Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency; Brigham and Womens Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre -
G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Volume: 12 Page(s): S696 - S696
01/01/2017 Authors: Hart L; Roberts P; Ferrarotto R; Bordoni R; Conkling P; Pati T; Lima CMR; Owonikoko T; Schuster S; Jotte R -
Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo plus Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)
Volume: 12 Page(s): S261 - S262
01/01/2017 Authors: Owonikoko T; Nackaerts K; Csoszi T; Ostoros G; Baik C; Ullmann CD; Zagadailov E; Sheldon-Waniga E; Huebner D; Leonard EJ -
Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial
Volume: 12 Page(s): S406 - S407
01/01/2017 Authors: Byers LA; Krug L; Wagar S; Dowlati A; Hann C; Chiappori A; Owonikoko T; Woe K; Bensman Y; Hurtado B -
Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER-MEDICARE Analysis
Volume: 12 Page(s): S703 - S704
01/01/2017 Authors: Kim S; Ragin C; Chen Z; Behera M; Pillai R; Steuer C; Belani C; Khuri F; Ramalingam S; Owonikoko T -
Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Volume: 12 Page(s): S253 - S254
01/01/2017 Authors: Pillai R; Behera M; Owonikoko T; Kamphorst A; Pakkala S; Belani C; Khuri F; Ahmed R; Ramalingam S -
Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Volume: 12 Page(s): S470 - S470
01/01/2017 Authors: Behera M; Gillespie T; Liu Y; Jia Y; Higgins K; Steuer C; Saba N; Shin D; Pakkala S; Pillai R -
Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non-Small Cell Lung Cancer
Volume: 12 Page(s): S855 - S856
01/01/2017 Authors: Ahmed H; Liu Y; O'Conne K; Gillespie T; Ahmed M; Pate P; Pillai R; Behera M; Steuer C; Owonikoko T -
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.
Oncology Volume: 93 Page(s): 336 - 342
01/01/2017 Authors: Evans M; Liu Y; Chen C; Steuer C; Cassidy R; Landry J; Higgins K; Beitler JJ; Willingham F; Owonikoko TK -
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
Cancer Immunol Immunother Volume: 66 Page(s): 45 - 50
01/01/2017 Authors: Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A -
National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys Volume: 97 Page(s): 128 - 137
01/01/2017 Authors: Higgins KA; O'Connell K; Liu Y; Gillespie TW; McDonald MW; Pillai RN; Patel KR; Patel PR; Robinson CG; Simone CB -
Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
PLoS One Volume: 12 Page(s): e0170187
01/01/2017 Authors: Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J -
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Lancet Oncol Volume: 17 Page(s): 1661 - 1671
12/01/2016 Authors: Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL -
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.
Mol Cell Volume: 64 Page(s): 859 - 874
12/01/2016 Authors: Fan J; Lin R; Xia S; Chen D; Elf SE; Liu S; Pan Y; Xu H; Qian Z; Wang M -
Systemic treatment and management approaches for medullary thyroid cancer.
Cancer Treat Rev Volume: 50 Page(s): 89 - 98
11/01/2016 Authors: Ernani V; Kumar M; Chen AY; Owonikoko TK -
A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy
Volume: 11 Page(s): S306 - S307
11/01/2016 Authors: Owonikoko T; Ready N; Postmus P; Reck M; Peters S; Pieters A; Selvaggi G; Fairchild J; Govindan R -
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy: Topic: Medical Oncology.
J Thorac Oncol Volume: 11 Page(s): S306 - S307
11/01/2016 Authors: Owonikoko T; Ready N; Postmus P; Reck M; Peters S; Pieters A; Selvaggi G; Fairchild J; Govindan R -
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Cancer Lett Volume: 380 Page(s): 494 - 504
10/01/2016 Authors: Shi P; Oh Y-T; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK -
Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older.
Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E468
10/01/2016 Authors: Higgins KA; Jia Y; Liu Y; Force S; Fernandez F; Ramalingam S; Behera M; Owonikoko TK; Pillai RN; Simone CB -
Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis.
Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E438 - E439
10/01/2016 Authors: Higgins KA; O'Connell K; Liu Y; Patel PR; Pillai RN; Owonikoko TK; Simone CB; Robinson CG; McDonald MW; Gillespie TW -
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
Oncologist Volume: 21 Page(s): 1163 - 1164
10/01/2016 Authors: Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J -
Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis
Volume: 96 Page(s): E438 - E439
10/01/2016 Authors: Higgins KA; O'Connell K; Liu Y; Patel PR; Pillai RN; Owonikoko TK; Simone CB; Robinson CG; McDonald MW; Gillespie TW -
Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older
Volume: 96 Page(s): E468 - E468
10/01/2016 Authors: Higgins KA; Jia Y; Liu Y; Force S; Fernandez F; Ramalingam S; Behera M; Owonikoko TK; Pillai RN; Simone CB -
Lung Stereotactic Body Radiation Therapy (SBRT) Versus Pneumonectomy in Patients With Non-Small Cell Lung Cancer (NSCLC) Ages 70 or Older
Volume: 96 Page(s): E468 - E468
10/01/2016 Authors: Higgins KA; Jia Y; Liu Y; Force S; Fernandez F; Ramalingam S; Behera M; Owonikoko TK; Pillai RN; Simone CB -
Better Overall Survival with Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis
Volume: 96 Page(s): E438 - E439
10/01/2016 Authors: Higgins KA; O'Connell K; Liu Y; Patel PR; Pillai RN; Owonikoko TK; Simone CB; Robinson CG; McDonald MW; Gillespie TW -
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.
Volume: 17 Page(s): e57 - e64
09/01/2016 Authors: Behera M; Owonikoko TK; Gal AA; Steuer CE; Kim S; Pillai RN; Khuri FR; Ramalingam SS; Sica GL -
c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors
Volume: 76
07/01/2016 Authors: Shi P; Oh Y-T; Zhang G; Yao W; Yue P; Kanteti R; Riehm J; Salgia R; Owonikoko T; Ramalingam SS -
An evaluation of NGS to identify gene fusions using RNA from FFPE solid tumor samples
Volume: 76
07/01/2016 Authors: Parks JT; Byron L; Crain B; June S; Chen Z; Du T; Sica GL; Owonikoko TK; Neill SG; Newman S -
Mcl-1 dictates DNA double-strand break repair pathway choice
Volume: 76
07/01/2016 Authors: Chen G; Xu K; Xie M; Owonikoko TK; Ramalingam SS; Doetsch PW; Deng X -
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Cancer Discov Volume: 6 Page(s): 601 - 611
06/01/2016 Authors: Konduri K; Gallant J-N; Chae YK; Giles FJ; Gitlitz BJ; Gowen K; Ichihara E; Owonikoko TK; Peddareddigari V; Ramalingam SS -
Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.
Volume: 34
05/20/2016 Authors: Evans M; Liu Y; Chen C; Gillespie TW; Steuer CE; Owonikoko TK; Ramalingam SS; Beitler JJ; El-Rayes BF; Fernandez F -
Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base
Volume: 34
05/20/2016 Authors: Naik K; Liu Y; Goodman M; Gillespie TW; El-Rayes BF; Pickens A; Force S; Steuer CE; Owonikoko TK; Ramalingam SS -
Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).
Volume: 34
05/20/2016 Authors: Behera M; Gillespie TW; Liu Y; Jia Y; Higgins KA; Steuer CE; Saba NF; Shin DM; Pakkala S; Pillai RN -
National Cancer Data Base analysis of proton versus photon radiotherapy in non-small cell lung cancer(NSCLC).
Volume: 34
05/20/2016 Authors: Behera M; OConnell KA; Liu Y; Gillespie TW; Pillai RN; Patel P; Simone CB; Robinson CG; Owonikoko TK; Belani CP -
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
Volume: 34
05/20/2016 Authors: Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS -
A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).
Volume: 34
05/20/2016 Authors: Pietanza MC; Krug LM; Waqar SN; Dowlati A; Hann CL; Chiappori A; Owonikoko TK; Woo K; Bensman Y; Hurtado B -
Role of anti-EGFR monoclonal antibody in EGFR FISH positive NSCLC patients: A meta-analysis of phase III randomized controlled trials.
Volume: 34
05/20/2016 Authors: Patel N; Behera M; Pillai RN; Owonikoko TK; Pakkala S; Belani CP; Khuri FR; Ramalingam SS -
A correlative analysis of PDL-1, PD-1, and EGFR, HER2, HER3 expression in oropharyngeal squamous cell carcinoma (OPSCC).
Volume: 34
05/20/2016 Authors: Steuer CE; Griffith CC; Liu Y; Magliocca KR; Patel M; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF -
Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.
Volume: 34
05/20/2016 Authors: Cascone T; Subbiah V; Hess KR; Nelson S; Nilsson MB; Subbiah IM; Ali SM; Carbone DP; Salgia R; Owonikoko TK -
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
J Transl Med Volume: 14 Page(s): 111
05/03/2016 Authors: Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R -
Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
Support Care Cancer Volume: 24 Page(s): 1789 - 1793
04/01/2016 Authors: McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF -
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
J Thorac Oncol Volume: 11 Page(s): 453 - 474
04/01/2016 Authors: Bunn PA; Minna JD; Augustyn A; Gazdar AF; Ouadah Y; Krasnow MA; Berns A; Brambilla E; Rekhtman N; Massion PP -
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Cancer Volume: 122 Page(s): 766 - 772
03/01/2016 Authors: Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA -
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
J Mol Diagn Volume: 18 Page(s): 299 - 315
03/01/2016 Authors: Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS -
Phosphorylated Bcl-2 and Mcl-1 as prognostic markers in small cell lung cancer.
Oncotarget
02/18/2016 Authors: Chowdry RP; Sica GL; Kim S; Chen Z; Goodman A; Alexis D; Deng X; Owonikoko TK -
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Oncogene Volume: 35 Page(s): 459 - 467
01/28/2016 Authors: Oh Y-T; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun S-Y -
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
Cancer Volume: 122 Page(s): 50 - 60
01/01/2016 Authors: Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS -
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
Cancer Chemother Pharmacol Volume: 77 Page(s): 155 - 162
01/01/2016 Authors: Owonikoko TK; Hussain A; Stadler WM; Smith DC; Kluger H; Molina AM; Gulati P; Shah A; Ahlers CM; Cardarelli PM -
Analysis of liver-directed therapies in U.S. cancer patients.
Curr Oncol Volume: 22 Page(s): e457 - e461
12/01/2015 Authors: Alese OB; Kim S; Chen Z; Ramalingam SS; Owonikoko TK; El-Rayes BF -
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.
Mol Aspects Med Volume: 45 Page(s): 55 - 66
11/01/2015 Authors: Kumar M; Ernani V; Owonikoko TK -
Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs.
Cancer Volume: 121 Page(s): 3390 - 3392
10/01/2015 Authors: Owonikoko TK -
Relationship between EGFR Mutation Status and Response to Specific Chemotherapeutic Agents in Patients with Stage IV Non-Small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S525 - S525
09/01/2015 Authors: Ernani V; Chatwal MS; Kumar M; Zhang C; Chen Z; Owonikoko TK; Ramalingam SS -
Treatment of Advanced SCLC Including Second Line
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S145 - S145
09/01/2015 Authors: Owonikoko TK -
A Phase 2, Single Arm Study of Lucitanib in Patients with Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF-Related Genetic Changes
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S551 - S552
09/01/2015 Authors: Spigel DR; Felip E; Novello S; Garassino MC; Collins M; Litten JB; Allen AR; Cereda R; Owonikoko TK; Socinski MA -
Patterns of Disease Progression for Stage IV NSCLC While on PD-1 Directed Therapy as Compared to Standard Chemotherapy
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S644 - S644
09/01/2015 Authors: Chatwal MS; Ernani V; Owonikoko TK; Ramalingam SS; Pillai RN -
Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S545 - S545
09/01/2015 Authors: Kumar M; Ragin C; Zhang C; Chen Z; Han EJ; Ernani V; Behera M; Steuer C; Saba N; Shin D -
Alisertib (MLN8237)+Paclitaxel versus Placebo plus Paclitaxel for Relapsed SCLC
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S625 - S626
09/01/2015 Authors: Owonikoko TK; Csoszi T; Nackaerts K; Santos E; Baik CS; Juhasz E; Kolek V; Ostoros G; Roubec J; Borghaei H -
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Descriptive Analysis and Overall Survival
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S355 - S355
09/01/2015 Authors: Kumar M; Zhang C; Chen Z; Nelson M; Ernani V; Staton G; Veeraraghavan S; Gal A; Sica G; Owonikoko TK -
Survival Impact of Adjuvant Radiation and Chemotherapy in Patients with Typical and Atypical Pulmonary Carcinoids
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S507 - S507
09/01/2015 Authors: Hannan LM; Switchenko J; Liu Y; Behera M; Higgins KA; Fernandez F; Pillai RN; Khuri F; Ramalingam SS; Gillespie TW -
A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide Concurrent with Thoracic Radiation for Stage III NSCLC Patients
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S212 - S212
09/01/2015 Authors: Steuer C; Behera M; Higgins KA; Saba N; Shin D; Pakkala S; Pillai R; Owonikoko TK; Curran WJ; Belani CP -
Squamous Cell Carcinoma of Lung in the United States: Analysis of the National Cancer Database (NCDB)
JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S367 - S367
09/01/2015 Authors: Behera M; Owonikoko TK; Liu Y; Gillespie TW; Yuan M; Pillai RN; Steuer C; Higgins KA; Pakkala S; Belani CP -
A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease.
World J Oncol Volume: 6 Page(s): 416 - 420
08/01/2015 Authors: Bangaru SD; Kozarsky PE; Lee DJ; Sica GL; Owonikoko TK -
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
J Thorac Oncol Volume: 10 Page(s): 1142 - 1147
08/01/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS -
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
Cancer Lett Volume: 364 Page(s): 70 - 78
08/01/2015 Authors: Yao W; Yue P; Zhang G; Owonikoko TK; Khuri FR; Sun S-Y -
Development of Bcl2 BH4 antagonist for cancer therapy
Volume: 75
08/01/2015 Authors: Han B; Park D; Li R; Xie M; Owonikoko T; Sica G; Ding C; Zhou J; Magis A; Ramalingam S -
Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients
Volume: 75
08/01/2015 Authors: Kamphorst AO; Pillai RN; Yang S; Akondy R; Koenig L; Yu K; McCausland M; Sica G; Khuri FR; Owonikoko TK -
A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
Volume: 75
08/01/2015 Authors: Owonikoko TK; Harvey RD; Lewis C; Chen Z; Kauh JS; Renfroe M; Deovic R; Sica GL; Carthon BC; Harris WB -
Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Contemp Clin Trials Volume: 43 Page(s): 133 - 141
07/01/2015 Authors: Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J -
Development and testing of a tool to assess patient preferences for phase I clinical trial participation.
Psychooncology Volume: 24 Page(s): 835 - 838
07/01/2015 Authors: Pentz RD; Hendershot KA; Wall L; White TE; Peterson SK; Thomas CB; McCormick J; Green MJ; Lewis C; Farmer ZL -
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).
Lung Cancer Volume: 89 Page(s): 66 - 70
07/01/2015 Authors: Owonikoko TK; Dahlberg SE; Khan SA; Gerber DE; Dowell J; Moss RA; Belani CP; Hann CL; Aggarwal C; Ramalingam SS -
Genomic Classification of Cutaneous Melanoma.
Cell Volume: 161 Page(s): 1681 - 1696
06/18/2015 Authors: Cancer Genome Atlas Network -
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Cancer Cell Volume: 27 Page(s): 852 - 863
06/08/2015 Authors: Han B; Park D; Li R; Xie M; Owonikoko TK; Zhang G; Sica GL; Ding C; Zhou J; Magis AT -
Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States.
World J Oncol Volume: 6 Page(s): 349 - 354
06/01/2015 Authors: Alese OB; Kim S; Chen Z; Shaib W; Staley CA; Ramalingam SS; Owonikoko TK; El-Rayes BF -
Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction.
Cancer Volume: 121 Page(s): 1772 - 1778
06/01/2015 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF -
Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis.
Oral Oncol Volume: 51 Page(s): 586 - 592
06/01/2015 Authors: Joseph LJ; Goodman M; Higgins K; Pilai R; Ramalingam SS; Magliocca K; Patel MR; El-Deiry M; Wadsworth JT; Owonikoko TK -
Comparative genomics of pulmonary and extrapulmonary small cell carcinoma.
Volume: 33
05/20/2015 Authors: Sica G; Hanley K; Newman S; Mosunjac M; Martinez A; Han E; Zhang G; Ramalingam SS; Khuri FR; Rossi MR -
Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data
Volume: 33
05/20/2015 Authors: Saba NF; Newman S; Rossi MR; Steuer CE; Zhang H; Patel M; Wadsworth JT; El-Deiry M; Magliocca KR; Owonikoko TK -
Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
Volume: 33
05/20/2015 Authors: Behera M; Steuer CE; Fernandez F; Liu Y; Fu C; Gillespie TW; Higgins KA; Saba NF; Pillai RN; Force S -
Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis.
Volume: 33
05/20/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Pakkala S; Steuer CE; Saba NF; Shin DM; Belani CP; Khuri FR; Ramalingam SS -
Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States
Volume: 33
05/20/2015 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF -
Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.
Volume: 33
05/20/2015 Authors: Alese OB; Kim S; Chen Z; Shaib WL; Owonikoko TK; El-Rayes BF -
PD-L1, PD-1, and CTLA-4 as prognostic biomarkers in resected non-small cell lung cancer.
Volume: 33
05/20/2015 Authors: Owonikoko TK; Kowalski J; Kim S; Dwivedi B; Chen Z; Behera M; Mayfield W; Hermann RC; Chen L; Khuri FR -
Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes.
Volume: 33
05/20/2015 Authors: Owonikoko TK; Nelson M; Park SY; Kim S; Steuer CE; Behera M; Chen Z; Han E; Kumar M; Ernani V -
GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Oncotarget Volume: 6 Page(s): 8974 - 8987
04/20/2015 Authors: Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Clin Cancer Res Volume: 21 Page(s): 1859 - 1868
04/15/2015 Authors: Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD -
Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis.
Lung Cancer Volume: 88 Page(s): 80 - 84
04/01/2015 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai R; Saba NF; Shin DM; Owonikoko TK; Khuri FR -
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
Ther Adv Med Oncol Volume: 7 Page(s): 56 - 62
03/01/2015 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z; Rossi MR; Adsay NV -
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis.
J Thorac Oncol Volume: 10 Page(s): 479 - 485
03/01/2015 Authors: Steuer CE; Behera M; Kim S; Chen Z; Saba NF; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS -
Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.
J Thorac Oncol Volume: 10 Page(s): 462 - 471
03/01/2015 Authors: Mikell JL; Gillespie TW; Hall WA; Nickleach DC; Liu Y; Lipscomb J; Ramalingam SS; Rajpara RS; Force SD; Fernandez FG -
Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer.
J Clin Oncol Volume: 33 Page(s): 534 - 536
02/20/2015 Authors: Owonikoko TK; Ramalingam SS -
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.
J Clin Oncol Volume: 33 Page(s): 433 - 441
02/10/2015 Authors: Ramalingam SS; Shtivelband M; Soo RA; Barrios CH; Makhson A; Segalla JGM; Pittman KB; Kolman P; Pereira JR; Srkalovic G -
Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation.
Nucleic Acids Res Volume: 43 Page(s): 960 - 972
01/01/2015 Authors: Xie M; Park D; You S; Li R; Owonikoko TK; Wang Y; Doetsch PW; Deng X -
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
Cancer Volume: 120 Page(s): 3940 - 3951
12/15/2014 Authors: Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J -
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Cancer Med Volume: 3 Page(s): 1579 - 1594
12/01/2014 Authors: Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM -
Higher Dose of Palliative Thoracic Radiation Is Associated With Improved Survival for Patients With Stage IV Non-Small Cell Lung Cancer
Volume: 90 Page(s): S48 - S48
11/15/2014 Authors: Rajpara RS; Gillespie TW; Nickleach DC; Liu Y; Lipscomb J; Fernandez FG; Mikell JL; Ramalingam SS; Owonikoko TK; Pillai RN -
A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
Volume: 90 Page(s): S68 - S69
11/15/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS -
Postoperative Radiation Therapy (PORT) Is Associated With Better Survival in Non-Small Cell Lung Cancer With Involved N2 Lymph Nodes
Volume: 90 Page(s): S18 - S18
11/15/2014 Authors: Mikell JL; Gillespie TW; Hall WA; Nickleach DC; Liu Y; Lipscomb J; Ramalingam SS; Rajpara RS; Force SD; Fernandez FG -
Evaluation of Hospitalization Trends in Lung Cancer Patients With Hyponatremia
Volume: 90 Page(s): S62 - S62
11/15/2014 Authors: Kazi HA; Behera M; Steuer C; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS -
Clinical and Pathologic Characterization of Folate Receptor Alpha, Mesothelin, and Endosialin Expression in Mesotheliomas
Volume: 90 Page(s): S29 - S29
11/15/2014 Authors: Owonikoko TK; Busari A; Chen Z; Kim S; Alexis D; Somers EB; O'Shannessy DJ; Ramalingam S; Khuri F; Sica GL -
Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis
Volume: 90 Page(s): S50 - S51
11/15/2014 Authors: Steuer C; Behera M; Rossi M; Fisher K; Sica G; Gal A; Pakkala S; Pillai R; Owonikoko T; Khuri F -
Ethnic, gender, and age disparities and outcome of phase I clinical trials of biologically targeted anticancer agents
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION Volume: 23
11/01/2014 Authors: Owonikoko TK; Lewis C; Busari AK; Kim S; Chen Z; Lawson DH; Carthon BC; El-Rayes BF; Khuri FR; Kauh J -
Integrated genomic characterization of papillary thyroid carcinoma.
Cell Volume: 159 Page(s): 676 - 690
10/23/2014 Authors: Cancer Genome Atlas Research Network -
Evaluating markers of cisplatin sensitivity and survival in small cell lung cancer
Volume: 74
10/01/2014 Authors: Owonikoko TK; Zhang G; Sica GL; Chen Z; Switchenko JM; Kim S; Gal AA; Ramalingam SS; Deng X; Rossi MR -
Pharmacological inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs cancer cell response to DR5 activation-induced apoptosis
Volume: 74
10/01/2014 Authors: Oh Y-T; Yue P; Owonikoko TK; Khuri FR; Sun S-Y -
Preserved histological and molecular phenotypes following serial in vivo propagation of patient-derived xenografts of small cell lung cancer
Volume: 74
10/01/2014 Authors: Owonikoko TK; Zhang G; Sica GL; Kim HS; Ogee-Nwankwo OC; Ramalingam SS; Rossi MR; Khuri FR -
Development of small molecule Bax agonists for lung cancer treatment
Volume: 74
10/01/2014 Authors: Xin M; Li R; Park D; Owonikoko TK; Sica GL; Corsino PE; Ding JZC; Magis AT; Ramalingam SS; Curran WJ -
Small-molecule Bax agonists for cancer therapy.
Nat Commun Volume: 5 Page(s): 4935
09/17/2014 Authors: Xin M; Li R; Xie M; Park D; Owonikoko TK; Sica GL; Corsino PE; Zhou J; Ding C; White MA -
EVALUATION OF HOSPITALIZATION TRENDS IN LUNG CANCER PATIENTS WITH HYPONATREMIA
JOURNAL OF THORACIC ONCOLOGY Volume: 9 Page(s): S182 - S182
09/01/2014 Authors: Kazi HA; Behera M; Steuer C; Owonikoko T; Pillai R; Ramalingam SS; Khuri FR -
A Comparison of Palliative Inpatient Management Strategies for Cancer-Related Superior Vena Cava Obstruction
Volume: 90 Page(s): S80 - S81
09/01/2014 Authors: Hall WA; Steuer CE; Nickleach DC; Behera M; Owonikoko TK; Higgins KA; Khuri FR; Curran WJ; Ramalingam SS -
Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review.
Oral Oncol Volume: 50 Page(s): 888 - 894
09/01/2014 Authors: Behera M; Owonikoko TK; Kim S; Chen Z; Higgins K; Ramalingam SS; Shin DM; Khuri FR; Beitler JJ; Saba NF -
Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
Cell Death Differ Volume: 21 Page(s): 1160 - 1169
07/01/2014 Authors: Wang B; Xie M; Li R; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Wang Y; Deng X -
HPV-associated lung cancers: an international pooled analysis.
Carcinogenesis Volume: 35 Page(s): 1267 - 1275
06/01/2014 Authors: Ragin C; Obikoya-Malomo M; Kim S; Chen Z; Flores-Obando R; Gibbs D; Koriyama C; Aguayo F; Koshiol J; Caporaso NE -
Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.
Volume: 32
05/20/2014 Authors: Joseph L; Goodman M; Higgins KA; Pilai R; Ramalingam SS; Owonikoko TK; Beitler JJ; Shin DM; Khuri FR; Saba NF -
Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy
Volume: 32
05/20/2014 Authors: Behera M; Ragin C; Kim S; Chen Z; Steuer CE; Saba NF; Pillal RN; Belani CP; Ramalingam SS; Khuri FR -
Clinical characteristics and outcomes of atypical carcinoid (AC) tumor of the lung: A Surveillance, Epidemiology, and End Results database analysis.
Volume: 32
05/20/2014 Authors: Steuer CE; Behera M; Kim S; Chen Z; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS -
A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ceRCC) and B-cell non Hodgkin lymphoma (B-NHL)
Volume: 32
05/20/2014 Authors: Owonikoko TK; Hussain A; Stadler WM; Smith DC; Sznol M; Molina AM; Gulati P; Shah A; Ahlers CM; Cardarelli J -
Mortality from malignant bowel obstruction in hospitalized US cancer patients
Volume: 32
05/20/2014 Authors: Alese OB; Kim S; Chen Z; Owonikoko TK; El-Rayes BF -
Management approaches and outcomes of lung cancer patients hospitalized for malignant pleural effusions.
Volume: 32
05/20/2014 Authors: Behera M; Steuer CE; Kim S; Pillai RN; Chen Z; Owonikoko TK; Belani CP; Khuri FR; Ramalingam SS -
Current approaches to the treatment of metastatic brain tumours.
Nat Rev Clin Oncol Volume: 11 Page(s): 203 - 222
04/01/2014 Authors: Owonikoko TK; Arbiser J; Zelnak A; Shu H-KG; Shim H; Robin AM; Kalkanis SN; Whitsett TG; Salhia B; Tran NL -
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Head Neck Pathol Volume: 8 Page(s): 66 - 72
03/01/2014 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Owonikoko TK; Sarlis NJ; Eggers C; Phelan V; Grist WJ -
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
Cancer Prev Res (Phila) Volume: 7 Page(s): 283 - 291
03/01/2014 Authors: Saba NF; Hurwitz SJ; Kono SA; Yang CS; Zhao Y; Chen Z; Sica G; Mller S; Moreno-Williams R; Lewis M -
Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Contemp Clin Trials Volume: 37 Page(s): 322 - 332
03/01/2014 Authors: Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J -
Small cell lung cancer: therapies and targets.
Semin Oncol Volume: 41 Page(s): 133 - 142
02/01/2014 Authors: Pillai RN; Owonikoko TK -
Molecular Detection of Clinically Actionable Lung Cancer Mutations: Multiplexed Single Gene Assays Versus Next-Generation Sequencing Following Target-Enrichment
Volume: 27 Page(s): 476A - 477A
02/01/2014 Authors: Fisher KE; Wang J; Pillai RN; Owonikoko TK; Ramalingam SR; Khuri FR; Gal AA; Mann KP; Hill CE; Sica GL -
Molecular Detection of Clinically Actionable Lung Cancer Mutations: Multiplexed Single Gene Assays Versus Next-Generation Sequencing Following Target-Enrichment
Volume: 94 Page(s): 476A - 477A
02/01/2014 Authors: Fisher KE; Wang J; Pillai RN; Owonikoko TK; Ramalingam SR; Khuri FR; Gal AA; Mann KP; Hill CE; Sica GL -
Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
Cancer Res Volume: 74 Page(s): 212 - 223
01/01/2014 Authors: Xie M; Yen Y; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Doetsch PW; Deng X -
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Cancer Chemother Pharmacol Volume: 73 Page(s): 171 - 180
01/01/2014 Authors: Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH -
Altered glutamine metabolism and therapeutic opportunities for lung cancer.
Clin Lung Cancer Volume: 15 Page(s): 7 - 15
01/01/2014 Authors: Mohamed A; Deng X; Khuri FR; Owonikoko TK -
Taxanes: vesicants, irritants, or just irritating?
Ther Adv Med Oncol Volume: 6 Page(s): 16 - 20
01/01/2014 Authors: Barbee MS; Owonikoko TK; Harvey RD -
RANDOMIZED PHASE II STUDY OF SINGLE AGENT OSI-906, AN ORAL, SMALL MOLECULE, TYROSINE KINASE INHIBITOR (TKI) OF THE INSULIN GROWTH FACTOR-1 RECEPTOR (IGF-1R) VERSUS TOPOTECAN FOR THE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC)
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S930 - S931
11/01/2013 Authors: Chiappori AA; Otterson G; Dowlati A; Traynor A; Horn L; Hann C; Owonikoko T; Abu Hejleh T; Ross HJ; Nieva J -
A PHASE IB PREOPERATIVE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS IN OPERABLE NON SMALL CELL LUNG CANCER
JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S628 - S629
11/01/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Saba NF; Kono SA; Behera M; Lewis C; Chen Z; Pickens A -
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ann Oncol Volume: 24 Page(s): 2875 - 2880
11/01/2013 Authors: Ramalingam S; Crawford J; Chang A; Manegold C; Perez-Soler R; Douillard J-Y; Thatcher N; Barlesi F; Owonikoko T; Wang Y -
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Mol Cancer Ther Volume: 12 Page(s): 2200 - 2212
10/01/2013 Authors: Li R; Hu Z; Sun S-Y; Chen ZG; Owonikoko TK; Sica GL; Ramalingam SS; Curran WJ; Khuri FR; Deng X -
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
Cancer Lett Volume: 338 Page(s): 229 - 238
09/28/2013 Authors: Ren H; Zhao L; Li Y; Yue P; Deng X; Owonikoko TK; Chen M; Khuri FR; Sun S-Y -
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
Cancer Res Volume: 73 Page(s): 5485 - 5496
09/01/2013 Authors: Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X -
Paranasal Sinus Squamous Cell Carcinoma Incidence and Survival Based on Surveillance, Epidemiology, and End Results Data, 1973 to 2009
CANCER Volume: 119 Page(s): 2602 - 2610
07/15/2013 Authors: Ansa B; Goodman M; Ward K; Kono SA; Owonikoko TK; Higgins K; Beitler JJ; Grist W; Wadsworth T; El-Deiry M -
Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009.
Cancer Volume: 119 Page(s): 2602 - 2610
07/15/2013 Authors: Ansa B; Goodman M; Ward K; Kono SA; Owonikoko TK; Higgins K; Beitler JJ; Grist W; Wadsworth T; El-Deiry M -
Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
Volume: 31
05/20/2013 Authors: Saba NF; Kono SA; Mendel JR; Hurwitz SJ; Owonikoko TK; Lewis CM; Harvey D; Rogerio JW; Chen Z; Wadsworth T -
Integrating patients' values into decisions to enroll in phase I trials: A feasibility study.
Volume: 31
05/20/2013 Authors: Hendershot KA; Dossul T; Wall L; Owonikoko TK; Harvey RD; Thomas CB; McCormick JB; Khuri FR; Pentz RD -
Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract
Volume: 31
05/20/2013 Authors: Alese OB; El-Rayes BF; Sica G; Zhang G; Rossi MR; Adsay V; Alexis D; La Rosa FG; Varella-Garcia M; Chen Z -
Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review.
Volume: 31
05/20/2013 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS -
A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States.
Volume: 31
05/20/2013 Authors: Kang H; Kim S; Chen Z; El-Rayes BF; Brandes JC; Saba NF; Khuri FR; Ramalingam SS; Owonikoko TK -
Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation.
J Biol Chem Volume: 288 Page(s): 13215 - 13224
05/10/2013 Authors: Li Y; Wang X; Yue P; Tao H; Ramalingam SS; Owonikoko TK; Deng X; Wang Y; Fu H; Khuri FR -
Window of opportunity preoperative interrogation of mTOR pathway in patients with resectable non-small cell lung cancer (NSCLC).
Volume: 73
04/15/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Kono S; Behera M; Mendel J; Chen Z; Pickens A; Fu RW -
Development of small molecule BcI-XL inhibitors for treatment of lung cancer
Volume: 73
04/15/2013 Authors: Park D; Magis AT; Li R; Owonikoko TKK; Sica GL; Sun S-Y; Ramalingam SS; Khuri FR; Curran WJ; Deng X -
Poly (ADP) ribose polymerase (PARP) enzyme inhibitor, CEP8983, potentiates bendamustine activity in small cell lung cancer (SCLC)
Volume: 73
04/15/2013 Authors: Owonikoko TK; Zhang G; Yue P; Ramalingam S; Khuri FR; Sun S-Y -
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
Cancer Volume: 119 Page(s): 1503 - 1511
04/15/2013 Authors: Owonikoko TK; Hossain MS; Bhimani C; Chen Z; Kim S; Ramalingam SS; Sun S-Y; Shin DM; Waller EK; Khuri FR -
CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Clin Cancer Res Volume: 19 Page(s): 1603 - 1611
03/15/2013 Authors: Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG -
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Br J Cancer Volume: 108 Page(s): 762 - 765
03/05/2013 Authors: Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A -
Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables.
Clin Lung Cancer Volume: 14 Page(s): 128 - 138
03/01/2013 Authors: Behera M; Heine JJ; Sica GL; Fowler EE; Tran H; Fu RW; Gal AA; Hermann R; Mayfield W; Khuri FR -
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
J Thorac Oncol Volume: 8 Page(s): 369 - 372
03/01/2013 Authors: Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z -
Effect of the Duration of Cold Ischemic Time and Temperature Conditions on Maintenance of RNA Integrity Number (RIN) in Biospecimens
Volume: 26 Page(s): 485A - 485A
02/01/2013 Authors: Sica G; Butler C; Zhang G; Maithel S; Rossi M; Owonikoko T -
Effect of the Duration of Cold Ischemic Time and Temperature Conditions on Maintenance of RNA Integrity Number (RIN) in Biospecimens
Volume: 93 Page(s): 485A - 485A
02/01/2013 Authors: Sica G; Butler C; Zhang G; Maithel S; Rossi M; Owonikoko T -
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
Oncologist Volume: 18 Page(s): 600 - 610
01/01/2013 Authors: Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR -
Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials.
Oncologist Volume: 18 Page(s): 242 - 244
01/01/2013 Authors: Owonikoko TK -
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Oncologist Volume: 18 Page(s): 1262 - 1269
01/01/2013 Authors: Owonikoko TK; Chowdry RP; Chen Z; Kim S; Saba NF; Shin DM; Khuri FR -
Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETSTM)" for Cancer Phase I Clinical Trials.
Open Med Inform J Volume: 7 Page(s): 8 - 17
01/01/2013 Authors: Chen Z; Wang Z; Wang H; Owonikoko TK; Kowalski J; Khuri FR -
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Am Soc Clin Oncol Educ Book
01/01/2013 Authors: Owonikoko TK; Khuri FR -
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Cancer Lett Volume: 325 Page(s): 139 - 146
12/28/2012 Authors: Ren H; Chen M; Yue P; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)
CANCER RESEARCH Volume: 72
12/15/2012 Authors: Puhalla SL; Appleman LJ; Beumer JH; Tawbi H; Stoller RG; Owonikoko TK; Ramalingam SS; Belani CP; Brufsky AM; Abraham J -
c-Myc suppression of DNA double-strand break repair.
Neoplasia Volume: 14 Page(s): 1190 - 1202
12/01/2012 Authors: Li Z; Owonikoko TK; Sun S-Y; Ramalingam SS; Doetsch PW; Xiao Z-Q; Khuri FR; Curran WJ; Deng X -
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
Cancer Cell Volume: 22 Page(s): 585 - 600
11/13/2012 Authors: Hitosugi T; Zhou L; Elf S; Fan J; Kang H-B; Seo JH; Shan C; Dai Q; Zhang L; Xie J -
Unusual suspects: pulmonary opportunistic infections masquerading as tumor metastasis in a patient with adrenocorticotropic hormone-producing pancreatic neuroendocrine cancer.
Ther Adv Med Oncol Volume: 4 Page(s): 295 - 300
11/01/2012 Authors: Chowdry RP; Bhimani C; Delgado MA; Lee DJ; Dayamani P; Sica GL; Owonikoko TK -
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.
Cancer Volume: 118 Page(s): 4571 - 4578
09/15/2012 Authors: Pentz RD; White M; Harvey RD; Farmer ZL; Liu Y; Lewis C; Dashevskaya O; Owonikoko T; Khuri FR -
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data.
Cancer Volume: 118 Page(s): 4444 - 4451
09/15/2012 Authors: Ellington CL; Goodman M; Kono SA; Grist W; Wadsworth T; Chen AY; Owonikoko T; Ramalingam S; Shin DM; Khuri FR -
Parp Enzyme Inhibitor, Veliparib (ABT-888), Potentiates the Efficacy Of Chemotherapy And Radiation In Small Cell Lung Cancer (SCLC)
Volume: 7 Page(s): S278 - S278
09/01/2012 Authors: Owonikoko TK; Zhang G; Deng X; Li C; Beumer JH; Rossi MR; Ramalingam SS; Curran WJ; Sun S; Khuri FR -
Tissue Expression of Activated Phosphorylated Forms of Bcl2 and Mcl1 as Prognostic Markers in Small Cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S219 - S219
09/01/2012 Authors: Owonikoko TK; Chowdry RP; Chen Z; Goodman A; Kim S; Deng X; Gal A; Khuri FR; Ramalingam SS; Sica G -
A Systematic Analysis Of High-dose Radiation In The Treatment Of Surgically Unresectable, Locally Advanced Non-small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY Volume: 7 Page(s): S212 - S213
09/01/2012 Authors: Behera M; Beitler JJ; Bhimani C; Higgins K; Chen Z; Deng X; Curran WJ; Khuri FR; Ramalingam SS; Owonikoko TK -
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.
Lung Cancer Volume: 77 Page(s): 331 - 338
08/01/2012 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS -
Phase I study of vandetinib in combination with gemcitabine and oxaliplatin in advanced solid malignancies
Volume: 30
05/20/2012 Authors: Wang P; Owonikoko TK; Lin Y; Stoller RG; Petro DP; Park DM; Ramanathan RK; Chu E; Beumer JH; Appleman LJ -
Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors.
Volume: 30
05/20/2012 Authors: Chowdry RP; Sica G; Chen Z; Goodman A; Kim S; Deng X; Curran WJ; Gal AA; Khuri FR; Ramalingam SS -
Using CHFR expression to predict response and survival after first line treatment with carboplatin-paclitaxel in NSCLC.
Volume: 30
05/20/2012 Authors: Pillai RN; Brodie SA; Li G; Herman JG; Brock M; Owonikoko TK; Ramalingam SS; Khuri FR; Brandes JC -
Prognostic impact of circulating endothelial cell counts in patients with advanced non-small cell lung cancer
Volume: 30
05/20/2012 Authors: DeJoubner NJ; Kang H; Li Q; Harris WAC; Stewart R; Price A; Quyyumi A; Kono SA; Ramalingam SS; Owonikoko TK -
A systematic analysis of high-dose radiation in the treatment of surgically unresectable, locally advanced non-small cell lung cancer
Volume: 30
05/20/2012 Authors: Behera M; Beitler JJ; Bhimani C; Higgins K; Chen Z; Kim S; Deng X; Curran WJ; Khuri FR; Ramalingam SS -
Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN)
Volume: 30
05/20/2012 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Eggers C; Phelan VH; Kono SA; Owonikoko TK; Ramalingam SS -
Physicians' ability to correctly identify values important to cancer patients enrolled in phase I clinical trials.
Volume: 30
05/20/2012 Authors: Pentz RD; Liu Y; Wall L; Daugherty C; Green MJ; Hlubocky FJ; Peterson SK; Sun CC; Dixon M; Harvey RD -
A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies
Volume: 30
05/20/2012 Authors: Kauh JS; Harvey RD; Owonikoko TK; El-Rayes BF; Shin DM; Murali S; Lewis CM; Karol MD; Teofilovici F; Du Y -
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Volume: 30
05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF -
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.
J Thorac Oncol Volume: 7 Page(s): 866 - 872
05/01/2012 Authors: Owonikoko TK; Behera M; Chen Z; Bhimani C; Curran WJ; Khuri FR; Ramalingam SS -
NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKC/FAK loop.
Cancer Lett Volume: 318 Page(s): 106 - 113
05/01/2012 Authors: Shen J; Xu L; Owonikoko TK; Sun S-Y; Khuri FR; Curran WJ; Deng X -
c-Myc suppresses DNA double-strand break repair
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Li Z; Owonikoko TK; Sun S-Y; Xiao Z-Q; Doetsch PW; Khuri FR; Curran WJ; Deng X -
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Cancer Biol Ther Volume: 13 Page(s): 272 - 280
03/01/2012 Authors: Li Y; Fan S; Koo J; Yue P; Chen ZG; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
J Biol Chem Volume: 287 Page(s): 257 - 267
01/02/2012 Authors: Oh Y-T; Yue P; Zhou W; Balko JM; Black EP; Owonikoko TK; Khuri FR; Sun S-Y -
Research biopsies in phase I studies: views and perspectives of participants and investigators.
IRB Volume: 34 Page(s): 1 - 8
01/01/2012 Authors: Pentz RD; Harvey RD; White M; Farmer ZL; Dashevskaya O; Chen Z; Lewis C; Owonikoko TK; Khuri FR -
Rising incidence of mucosal melanoma of the head and neck in the United States.
J Skin Cancer Volume: 2012 Page(s): 231693
01/01/2012 Authors: Marcus DM; Marcus RP; Prabhu RS; Owonikoko TK; Lawson DH; Switchenko J; Beitler JJ -
Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells.
Mol Cancer Ther Volume: 11 Page(s): 45 - 56
01/01/2012 Authors: Liu Y; Sun S-Y; Owonikoko TK; Sica GL; Curran WJ; Khuri FR; Deng X -
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.
Cancer Volume: 118 Page(s): 164 - 172
01/01/2012 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JR; Saba NR; Shin DM; Curran WJ; Khuri FR -
Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data.
Biomed Eng Online Volume: 10 Page(s): 97
11/08/2011 Authors: Behera M; Fowler EE; Owonikoko TK; Land WH; Mayfield W; Chen Z; Khuri FR; Ramalingam SS; Heine JJ -
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy.
Cancer Biol Ther Volume: 12 Page(s): 549 - 555
09/15/2011 Authors: Xu C-X; Zhao L; Yue P; Fang G; Tao H; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway.
Oncogene Volume: 30 Page(s): 3802 - 3812
09/01/2011 Authors: Li C; Fan S; Owonikoko TK; Khuri FR; Sun S-Y; Li R -
A Phase 1 and Pharmacokinetic Study of Ganetespib (STA-9090), a Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Subjects With Advanced Solid Tumour Malignancies
Volume: 47 Page(s): S153 - S153
09/01/2011 Authors: Harvey RD; Lewis CM; Kauh JS; Owonikoko TK; Akintayo A; Karol M; Teofilovici F; Lufkin JM; Khuri FR; Ramalingam SS -
ANALYSIS OF MTOR SIGNALING PATHWAY BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH EVEROLIMUS AND DOCETAXEL IN A PHASE II CLINICAL TRIAL.
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S1039 - S1040
06/01/2011 Authors: Owonikoko TK; Ramalingam S; Subramanian J; Sica G; Chen Z; Behera M; Rogerio J; Saba N; Tighiouart M; Gal A -
A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S967 - S968
06/01/2011 Authors: Owonikoko TK; Force S; Sica G; Bechara R; Harvey RD; Sun S-Y; Saba N; Rogerio J; Gal A; Kono S -
Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
J Clin Oncol Volume: 29 Page(s): e14569
05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR -
Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.
J Clin Oncol Volume: 29 Page(s): 5585
05/20/2011 Authors: Hossain S; Bhimani C; Chen Z; Ramalingam SS; Shin DM; Cohen C; Khuri FR; Waller E; Owonikoko TK -
Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.
J Clin Oncol Volume: 29 Page(s): 7553
05/20/2011 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS -
Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
J Clin Oncol Volume: 29 Page(s): 7602
05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR -
Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
J Clin Oncol Volume: 29 Page(s): e13601
05/20/2011 Authors: Khuri FR; Owonikoko TK; Subramanian J; Sica G; Behera M; Saba NF; Chen Z; Tighiouart M; Shin DM; Sun S -
Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR -
Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Behera M; Owonikoko TK; Chen Z; Kono SA; Khuri FR; Belani CP; Ramalingam SS -
Salvage tyrosine kinase inhibitor therapy for differentiated and medullary thyroid cancer.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Chowdry RP; Bhimani C; Ramalingam SS; Khuri FR; Owonikoko TK -
Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Hossain S; Bhimani C; Chen Z; Ramalingam SS; Shin DM; Cohen C; Khuri FR; Waller E; Owonikoko TK -
Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR -
Elevated eukaryotic translation initiation factor 4E (eIF4E) is involved in erlotinib resistance
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Li Y; Koo J; Fan S; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
Oncogenic role of EAPII/TTRAP in lung cancer development and its activation of MAPK-ERK pathway
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Li C; Fan S; Owonikoko TK; Khuri FR; Sun S-Y; Li R -
Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Hossain MS; Bhimani C; Chen Z; Shin D; Ramalingam SS; Khuri FR; Edmund WK; Owonikoko TK -
Preclinical evaluation of Poly (ADP) Ribose Polymerase (PARP) enzyme inhibitor, ABT-888, in combination with cytotoxic agents in small cell lung cancer (SCLC)
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Owonikoko TK; Zhang G; Yue P; Ramalingam S; Khuri F; Sun S-Y -
Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients
CANCER RESEARCH Volume: 71
04/15/2011 Authors: Hossain MS; Bhimani C; Chen Z; Shin D; Ramalingam SS; Khuri FR; Edmund WK; Owonikoko TK -
Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
Oncology Volume: 81 Page(s): 12 - 20
01/01/2011 Authors: Saba NF; Goodman M; Ward K; Flowers C; Ramalingam S; Owonikoko T; Chen A; Grist W; Wadsworth T; Beitler JJ -
Mucosal Melanoma Of The Head and Neck: A Population-based Analysis, 1973-2007
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Volume: 81 Page(s): S533 - S533
01/01/2011 Authors: Marcus DM; Marcus RP; Prabhu RS; Owonikoko TK; Lawson DH; Beitler JJ -
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
PLoS One Volume: 6 Page(s): e20899
01/01/2011 Authors: Xu C-X; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun S-Y -
Lung cancer: New biological insights and recent therapeutic advances.
CA Cancer J Clin Volume: 61 Page(s): 91 - 112
01/01/2011 Authors: Ramalingam SS; Owonikoko TK; Khuri FR -
Lung cancer in the elderly: what's age got to do with it?
Oncology (Williston Park) Volume: 24 Page(s): 1120 - 1129
11/15/2010 Authors: Owonikoko TK; Ramalingam SS; Khuri FR -
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
Cancer Volume: 116 Page(s): 3903 - 3909
08/15/2010 Authors: Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun S-Y; Strychor S; Tighiouart M; Egorin MJ -
What is the role of maintenance therapy in the treatment of non-small cell lung cancer?
Ther Adv Med Oncol Volume: 2 Page(s): 229 - 235
07/01/2010 Authors: Jiang Y; Owonikoko TK; Ramalingam SS; Khuri FR; Belani CP -
HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JC; Saba NF; Curran WJ; Khuri FR; Ramalingam SS -
Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Owonikoko TK; Ramalingam SS; Behera M; Brandes JC; Saba NF; Bhimani C; Harichand-Herdt S; Shin DM; Khuri FR; Ragin C -
Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Kauh JS; Harvey RD; Lawson DH; Owonikoko TK; Tighiouart M; Ramalingam SS; Shin DM; Lewis CM; El-Rayes BF; Khuri FR -
THE BIOLOGICAL SIGNIFICANCE OF TARGETED THERAPIES: THE DEVELOPMENT OF MTOR INHIBITORS
JOURNAL OF THORACIC ONCOLOGY Volume: 5 Page(s): S27 - S27
05/01/2010 Authors: Khuri FR; Ramalingam SS; Owonikoko TK; Sun S-Y; Fu H -
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
Clin Cancer Res Volume: 16 Page(s): 2496 - 2504
05/01/2010 Authors: Owonikoko TK; Ramalingam SS; Belani CP -
Histone deacetylase (HDAC) enzyme inhibition potentiates taxanes and doxorubicin activity in thyroid cancer cell lines
CANCER RESEARCH Volume: 70
04/01/2010 Authors: Owonikoko TK; Zhang G; Ramalingam SS; Khuri FR; Sun S-Y -
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
Int J Cancer Volume: 126 Page(s): 743 - 755
02/01/2010 Authors: Owonikoko TK; Ramalingam SS; Kanterewicz B; Balius TE; Belani CP; Hershberger PA -
Targeting the IGF-1R in lung cancer prevention and therapy
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S189 - S190
09/01/2009 Authors: Owonikoko TK; Ramalingam S; Sun S-Y; Khuri FR -
Preoperative therapy for early-stage NSCLC: opportunities and challenges.
Oncology (Williston Park) Volume: 23 Page(s): 886 - 892
09/01/2009 Authors: Owonikoko TK; Khuri FR; Ramalingam SS -
A phase I study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S594 - S595
09/01/2009 Authors: Owonikoko TK; Ramalingam SS; Harvey D; Saba NF; Kauh J; Shin DM; Sun S-Y; Browning K; Tighiouart M; Khuri FR -
Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challenges OWONIKOKO Article Reviewed
ONCOLOGY-NEW YORK Volume: 23 Page(s): 886 - 892
09/01/2009 Authors: Owonikoko TK; Khuri FR; Ramalingam SS -
Phase 2 study of ABT-869 in combination with Carboplatin/Paclitaxel (CP) in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC): lead-in cohort results
JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S706 - S706
09/01/2009 Authors: Ramalingam S; Owonikoko T; Khuri F; Saba N; Wallace J; Qian J; Gupta N; Ricker J; Carlson D -
The role of cetuximab in the management of non-small-cell lung cancer.
Clin Lung Cancer Volume: 10 Page(s): 230 - 238
07/01/2009 Authors: Owonikoko TK; Sun S-Y; Ramalingam SS -
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
Volume: 27
05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS -
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial.
J Clin Oncol Volume: 27 Page(s): 2512
05/20/2009 Authors: Pentz RD; Khuri F; Kauh J; Owonikoko T; White MM; Harvey RD -
Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study.
J Clin Oncol Volume: 27 Page(s): 8060
05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS -
Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial
Volume: 27
05/20/2009 Authors: Pentz RD; Khuri F; Kauh J; Owonikoko T; White MM; Harvey RD -
The histone deacetylase inhibitor, vorinostat, increases carboplatin and paclitaxel activity in non-small cell lung cancer cells.
CANCER RESEARCH Volume: 69
05/01/2009 Authors: Owonikoko T; Ramalingam S; Kanterewicz B; Balius T; Belani C; Hershberger P -
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Curr Treat Options Oncol Volume: 9 Page(s): 313 - 325
12/01/2008 Authors: Owonikoko TK; Ramalingam S -
Management of Small-Cell Lung Cancer: Incremental Changes but Hope for the Future The Hann/Rudin Article Reviewed
ONCOLOGY-NEW YORK Volume: 22 Page(s): 1493 - +
11/30/2008 Authors: Dowell J; Minna JD -
Minimal progress, potential promise in small-cell lung cancer.
Oncology (Williston Park) Volume: 22 Page(s): 1495 - 1496
11/30/2008 Authors: Owonikoko T; Ramalingam S -
Management of Small-Cell Lung Cancer: Incremental Changes but Hope for the Future The Hann/Rudin Article Reviewed
ONCOLOGY-NEW YORK Volume: 22 Page(s): 1495 - 1496
11/30/2008 Authors: Owonikoko T; Ramalingam S -
Management of Small-Cell Lung Cancer: Incremental Changes but Hope for the Future The Hann/Rudin Article Reviewed
ONCOLOGY-NEW YORK Volume: 22 Page(s): 1498 - +
11/30/2008 Authors: Kalemkerian GP -
Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC)
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Owonikoko TK; Stoller RG; Petro D; Flaugh R; Hershberger PA; Belani CP; Argiris AE -
Small cell lung cancer in elderly patients: a review.
J Natl Compr Canc Netw Volume: 6 Page(s): 333 - 344
03/01/2008 Authors: Owonikoko TK; Ramalingam S -
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
J Clin Oncol Volume: 25 Page(s): 5570 - 5577
12/10/2007 Authors: Owonikoko TK; Ragin CC; Belani CP; Oton AB; Gooding WE; Taioli E; Ramalingam SS -
Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.
Nat Clin Pract Oncol Volume: 4 Page(s): 491 - 495
08/01/2007 Authors: Owonikoko T; Agha M; Balassanian R; Smith R; Raptis A -
The effect of P53 gene status on the interaction of vorinostat (Suberoylanilide Hydroxamic Acid-SAHA) with carboplatin in non-small cell lung cancer (NSCLC) cell lines
Volume: 25
06/20/2007 Authors: Hershberger P; Owonikoko TK; Ramalingam S; Belani CP -
Phase II study of irinotecan and paclitaxel for patients with recurrent small cell lung cancer (SCLC)
Volume: 25
06/20/2007 Authors: Owonikoko TK; Ramalingam S; Forster J; Shuai Y; Evans T; Gooding WE; Sulecki M; Belani CP -
Lung cancer in patients >= 80 years of age: Analysis of the national surveillance, epidemiology and end results (SEER) database.
Volume: 24 Page(s): 403S - 403S
06/20/2006 Authors: Owonikoko TK; Belani C; Cai C; Oton A; Potter D; Ramalingam S -
Lung cancer in patients 80 years of age: Analysis of the national surveillance, epidemiology and end results (SEER) database.
J Clin Oncol Volume: 24 Page(s): 7156
06/20/2006 Authors: Owonikoko TK; Belani C; Cai C; Oton A; Potter D; Ramalingam S -
Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: An analysis of the National Surveillance, Epidemiology and End Results (SEER) Database.
J Clin Oncol Volume: 24 Page(s): 7038
06/20/2006 Authors: Oton AB; Belani C; Cai C; Owonikoko T; Gooding W; Siegfried J; Ramalingam S -
Retrospective study of Clostridium difficile colitis in a community hospital
Volume: 100 Page(s): S276 - S276
09/01/2005 Authors: Nawaz I; Owonikoko T; Saroha S; Pepe R; Gordon S -
Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism.
Biol Psychiatry Volume: 55 Page(s): 766 - 771
04/01/2004 Authors: Szabo Z; Owonikoko T; Peyrot M; Varga J; Mathews WB; Ravert HT; Dannals RF; Wand G -
In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET.
J Nucl Med Volume: 45 Page(s): 94 - 100
01/01/2004 Authors: Owonikoko TK; Fabucci ME; Brown PR; Nisar N; Hilton J; Mathews WB; Ravert HT; Rauseo P; Sandberg K; Dannals RF -
Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.
J Nucl Med Volume: 43 Page(s): 678 - 692
05/01/2002 Authors: Szabo Z; McCann UD; Wilson AA; Scheffel U; Owonikoko T; Mathews WB; Ravert HT; Hilton J; Dannals RF; Ricaurte GA -
Investigation of estrogen regulation of adrenal and glomerular angiotensin-II (AT1) receptors by radioligand binding and C-11-L159, 884 PET imaging.
JOURNAL OF NUCLEAR MEDICINE Volume: 43 Page(s): 40P - 40P
05/01/2002 Authors: Owonikoko TK; Sandberg K; Brown PR; Nisar N; Hilton J; Mathews WB; Ravert HT; Rauseo P; Dannals RF; Szabo Z -
Effect of alcoholism on the serotonin transporter in the limbic system.
JOURNAL OF NUCLEAR MEDICINE Volume: 43 Page(s): 108P - 108P
05/01/2002 Authors: Szabo Z; Owonikoko TK; Gotjen D; Peyrot MF; Mathews WB; Hilton J; Ravert HT; Dannals RF; Wand GS -
Intratumoral genetic heterogeneity in Barrett adenocarcinoma.
Am J Clin Pathol Volume: 117 Page(s): 558 - 566
04/01/2002 Authors: Owonikoko T; Rees M; Gabbert HE; Sarbia M -
Effect of region of interest definition on the binding parameters of [11C](+)McN5652
EUROPEAN JOURNAL OF NUCLEAR MEDICINE Volume: 28 Page(s): 1107 - 1107
08/01/2001 Authors: Owonikoko TK; Varga J; Chen M; Scheffel U; Mathews WB; Ravert HT; Hilton J; Dannals RF; Ricaurte G; Szabo Z -
Comparative analysis of basaloid and typical squamous cell carcinoma of the oesophagus: a molecular biological and immunohistochemical study.
J Pathol Volume: 193 Page(s): 155 - 161
02/01/2001 Authors: Owonikoko T; Loberg C; Gabbert HE; Sarbia M -
Colorectal neoplasms: a retrospective study.
East Afr Med J Volume: 75 Page(s): 718 - 723
12/01/1998 Authors: Elesha SO; Owonikoko TK